Topical and systemic antifungal therapy for chronic rhinosinusitis by Head, Karen et al.
Cochrane Database of Systematic Reviews
Topical and systemic antifungal therapy for chronic
rhinosinusitis (Review)
Head K, Sharp S, Chong LY, Hopkins C, Philpott C
Head K, Sharp S, Chong LY, Hopkins C, Philpott C.
Topical and systemic antifungal therapy for chronic rhinosinusitis.
Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD012453.
DOI: 10.1002/14651858.CD012453.pub2.
www.cochranelibrary.com
Topical and systemic antifungal therapy for chronic rhinosinusitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
25ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
28DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
30REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 1 Generic HRQL (change from
baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Analysis 1.2. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 2 Adverse effects - epistaxis. . 63
Analysis 1.3. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 3 Adverse effects - headache. . 64
Analysis 1.4. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 4 Adverse effects - local irritation. 65
Analysis 1.5. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 5 CT score. . . . . . . 66
Analysis 2.1. Comparison 2 Systemic antifungal versus placebo/no treatment, Outcome 1 Severe adverse effects - hepatic
toxicity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Analysis 2.2. Comparison 2 Systemic antifungal versus placebo/no treatment, Outcome 2 Adverse effects - gastrointestinal
disturbances. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Analysis 2.3. Comparison 2 Systemic antifungal versus placebo/no treatment, Outcome 3 CT score - opacification %
change from baseline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Analysis 2.4. Comparison 2 Systemic antifungal versus placebo/no treatment, Outcome 4 CT score - obstruction score %
change from baseline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
68ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
71APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
87CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
87DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
87SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
88NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iTopical and systemic antifungal therapy for chronic rhinosinusitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Topical and systemic antifungal therapy for chronic
rhinosinusitis
Karen Head1, Steve Sharp2, Lee-Yee Chong3, Claire Hopkins4 , Carl Philpott5
1Cochrane ENT, NuffieldDepartment of Surgical Sciences, University of Oxford, Oxford, UK. 2National Institute for Health and Care
Excellence, Manchester, UK. 3UK Cochrane Centre, Oxford, UK. 4ENT Department, Guy’s Hospital, London, UK. 5Department of
Medicine, Norwich Medical School, University of East Anglia, Norwich, UK
Contact address: Karen Head, Cochrane ENT, Nuffield Department of Surgical Sciences, University of Oxford, UK Cochrane Centre,
Summertown Pavilion, 18 - 24 Middle Way, Oxford, UK. khead@cochrane.org, karenshead@hotmail.co.uk.
Editorial group: Cochrane ENT Group.
Publication status and date: New, published in Issue 9, 2018.
Citation: Head K, Sharp S, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis.
Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
This review adds to a series of reviews looking at primary medical management options for patients with chronic rhinosinusitis.
Chronic rhinosinusitis is common and characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal
blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps.
Antifungals have been suggested as a treatment for chronic rhinosinusitis.
Objectives
To assess the effects of systemic and topical antifungal agents in patients with chronic rhinosinusitis, including those with allergic fungal
rhinosinusitis (AFRS) and, if possible, AFRS exclusively.
Search methods
The Cochrane ENT Information Specialist searched the Cochrane ENT Trials Register; Cochrane Central Register of Controlled
Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources
for published and unpublished trials. The date of the search was 17 November 2017.
Selection criteria
Randomised controlled trials (RCTs) with at least a two-week follow-up period comparing topical or systemic antifungals with (a)
placebo, (b) no treatment, (c) other pharmacological interventions or (d) a different antifungal agent. We did not include post-surgical
antifungal use.
Data collection and analysis
We used the standard Cochrane methodological procedures. Our primary outcomes were disease-specific health-related quality of
life (HRQL), patient-reported disease severity and the significant adverse effects of hepatic toxicity (systemic antifungals). Secondary
outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse effects of
gastrointestinal disturbance (systemic antifungals) and epistaxis, headache or local discomfort (topical antifungals). We used GRADE
to assess the quality of the evidence for each outcome; this is indicated in italics.
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Main results
We included eight studies (490 adult participants). The presence of nasal polyps on examination was an inclusion criterion in three
studies, an exclusion criterion in one study and the remaining studies included a mixed population. No studies specifically investigated
the effect of antifungals in patients with AFRS.
Topical antifungal treatment versus placebo or no intervention
We included seven studies (437 participants) that used amphotericin B (six studies; 383 participants) and one that used fluconazole
(54 participants). Different delivery methods, volumes and concentrations were used.
Four studies reported disease-specific health-related quality of life using a range of instruments. We did not meta-analyse the results
due to differences in the instruments used, and measurement and reporting methods. At the end of treatment (one to six months) none
of the studies reported statistically significant differences between the groups (low-quality evidence - we are uncertain about the result).
Two studies reported disease severity using patient-reported symptom scores. Meta-analysis was not possible. At the end of treatment
(8 to 13 weeks) one study showed no difference and the second found that patients in the placebo group had less severe symptoms (very
low-quality evidence - we are very uncertain about the result).
In terms of adverse effects, topical antifungals may lead to more local irritation compared with placebo (risk ratio (RR) 2.29, 95%
confidence interval (CI) 0.61 to 8.62; 312 participants; 5 studies; low-quality evidence) but little or no difference in epistaxis (RR 0.97,
95% CI 0.14 to 6.63; 225 participants; 4 studies, low-quality evidence) or headache (RR 1.26, 95% CI 0.60 to 2.63; 195 participants;
3 studies; very low-quality evidence).
None of the studies found a difference in generic health-related quality of life (one study) or endoscopic score (five studies) between
the treatment groups. Three studies investigated CT scan; two found no difference between the groups and one found a significant
decrease in the mean percentage of air space occluded, favouring the antifungal group.
Systemic antifungal treatment versus placebo or no treatment
One study (53 participants) comparing terbinafine tablets against placebo reported that there may be little or no difference between
the groups in disease-specific health-related quality of life or disease severity score (both low-quality evidence). Systemic antifungals
may lead to more hepatic toxicity events (RR 3.35, 95% CI 0.14 to 78.60) but fewer gastrointestinal disturbances (RR 0.37, 95% CI
0.04 to 3.36), compared to placebo, although the evidence was of low quality.
This study did not find a difference in CT scan score between the groups. Generic health-related quality of life and endoscopic score
were not measured.
Other comparisons
We found no studies that compared antifungal agents against other treatments for chronic rhinosinusitis.
Authors’ conclusions
Due to the very low quality of the evidence, it is uncertain whether or not the use of topical or systemic antifungals has an impact on
patient outcomes in adults with chronic rhinosinusitis compared with placebo or no treatment. Studies including specific subgroups
(i.e. AFRS) are lacking.
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence for the benefits and harms of antifungal treatment in patients with chronic rhinosinusitis including those
with allergic fungal rhinosinusitis (AFRS).
Background
Chronic rhinosinusitis is a common condition characterised by inflammation of the nose and paranasal sinuses (a group of air-filled
spaces behind the nose, eyes and cheeks). Patients with chronic rhinosinusitis have at least two of the following symptoms for at least
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12 weeks: either a blocked nose and/or discharge from their nose (runny nose) and one of either pain/pressure in their face or a reduced
sense of smell (hyposmia). Some people also have nasal polyps, which are grape-like swellings of the normal nasal lining inside the
nasal passage and sinuses. Some people with chronic rhinosinusitis with nasal polyps are allergic to airborne fungus and this can cause
a specific type of condition called allergic fungal rhinosinusitis (AFRS).
Fungal spores are commonly found in the nose as they are in the air we breathe. It is not clear if fungus plays a role in all cases of chronic
rhinosinusitis but there is evidence that it may have a role in a subset of patients. Antifungal treatments work to kill fungal spores or to
stop them growing. Antifungal treatments for chronic rhinosinusitis are used either topically (put into the nose) or taken systemically
(by mouth).
Study characteristics
We included eight studies (490 adult participants). Seven studies (437 participants) investigated topical antifungals (nasal sprays or
irrigations) and one study (53 participants) investigated systemic antifungals (tablets). All studies compared antifungals to placebo or
no treatment. Most studies were well conducted and there was a mix of patients with chronic rhinosinusitis both with, and without,
nasal polyps.
Key results and quality of the evidence
At the end of at least four weeks treatment, none of the studies found that patients using antifungals (topical or systemic) had a better
quality of life or less severe symptoms than patients who used placebo or had no treatment.
Not many participants in the studies reported having adverse effects. Topical antifungals may lead to more nasal irritation compared
with placebo. It is uncertain if patients taking topical antifungals have more headaches or nosebleeds than with placebo.
For systemic antifungals, it is uncertain if patients using antifungals have more problems with their liver (hepatic toxicity) than with
placebo. Systemic antifungals may lead to fewer patients with gastrointestinal disturbances compared to placebo.
We found no studies that compared antifungal treatment with other treatments for chronic rhinosinusitis.
We assessed the quality of the evidence as either low (further research is very likely to have an important impact on our confidence in
the result) or very low (any estimate of the result is very uncertain), as some of the results are only from one or two studies, which do
not have a lot of participants. Moreover, the different studies reported outcomes using different measurement scales making it difficult
to draw conclusions.
Conclusions
Due to the very low quality of the evidence, it is uncertain whether or not the use of topical or systemic antifungals has an impact on
patient outcomes in adults with chronic rhinosinusitis compared with placebo or no treatment. More trials are needed to assess well-
defined patient populations (such as the AFRS subgroup) and to evaluate other antifungals that have not been assessed in randomised
controlled trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topical antifungal versus placebo/no treatment for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Intervention: topical ant if ungal
Comparison: placebo/ no treatment
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evi-
dence
(GRADE)
What happens
Without topical anti-
fungal
With topical antifungal Difference
Heath-related quality of
lif e (HRQL)
Assessed with: various
instruments
Follow-up: range 4
weeks to 6 months
of part icipants: 312
(5 RCTs)
4 studies (252 part icipants) using dif ferent disease-specif ic quality of lif e instruments reported no
stat ist ically signif icant dif f erence between the groups receiving topical ant if ungal and placebo in
terms of change f rom baseline or endpoint values
⊕⊕©©
LOW 1
Topical ant if ungals
may lead to lit t le or no
dif ference in disease-
specif ic health-related
quality of lif e, com-
pared to placebo, for
pat ients with chronic
rhinosinusit is
Disease severity score
Assessed with: various
scales
Follow-up: range 8
weeks to 13 weeks
of part icipants: 176
(2 RCTs)
2 studies (all pat ients with chronic rhinosinusit is with nasal polyps) reported a disease severity
score using dif ferent symptoms. Ebbens 2006 (116 part icipants) reported mean change f rom
baseline and found that both the placebo and ant if ungal group only had small mean changes f rom
baseline, which were not stat ist ically signif icant between the groups (P = 0.31). Weschta 2004 (60
part icipants) reported the median disease severity scores at the end of treatment. They found that
the median symptom score in the placebo group was signif icant ly lower (fewer symptoms) than
the topical ant if ungal group (P < 0.05).3
⊕©©©
VERY LOW 2
It is uncertain whether
topical ant if ungals im-
prove disease sever-
ity scores compared to
placebo for people with
chronic rhinosinusit is
Generic HRQL (change
f rom baseline)
Assessed with: SF-
36 physical component
(higher = better)
Scale f rom: 0 to 100
Follow-up: mean 13
- The mean change f rom
baseline in the SF-
36 physical component
score without topical
ant if ungals was 1.4
points
- MD 0.8 points lower
(3.66 lower to 2.06
higher)
⊕⊕©©
LOW 7
There may be lit t le or
no dif ference in generic
quality of lif e (phys-
ical component) be-
tween topical ant if un-
gals and placebo for pa-
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weeks
of part icipants: 116
(1 RCT)
t ients with chronic rhi-
nosinusit is
Generic HRQL (change
f rom baseline)
Assessed with: SF-
36 mental component
(higher = better)
Scale f rom: 0 to 100
Follow-up: mean 13
weeks
of part icipants: 116
(1 RCT)
- The mean change f rom
baseline in SF-36 men-
tal component score
without topical ant if un-
gal was 1.9 points
- MD 2.2 points lower
(5.46 lower to 1.06
higher)
⊕⊕©©
LOW 7
There may be lit t le
or no dif ference in
generic quality of lif e
(physical component)
between the use of
topical ant if ungals and
placebo for pat ients
with chronic rhinosi-
nusit is
Adverse ef fects - epis-
taxis
Follow-up: range 4
weeks to 6 months
of part icipants: 225
(4 RCTs)
RR 0.97 (95%CI 0.14 to
6.63)
Study populat ion ⊕⊕©©
LOW 4
It is uncertain whether
topical ant if ungals in-
crease the risk of
epistaxis compared to
placebo for pat ients
with chronic rhinosi-
nusit is
1.9% 1.8%
(0.3 to 12.5)
0.1% fewer
(1.6 fewer to 10.6
more)
Adverse ef fects -
headache
Follow-up: range 4
weeks to 6 months
of part icipants: 195
(3 RCTs)
RR 1.26 (95%CI 0.60 to
2.63)
Study populat ion ⊕©©©
VERY LOW 5
It is uncertain whether
topical ant if ungals in-
crease the risk of
headache compared to
placebo for pat ients
with chronic rhinosi-
nusit is
11.0% 13.8%
(6.6 to 28.9)
2.9%more
(4.4 fewer to 17.9
more)
Adverse ef fects - local
irritat ion
Follow-up: range 4
weeks to 6 months
of part icipants: 312
(5 RCTs)
RR 2.29 (95%CI 0.61 to
8.62)
Study populat ion ⊕⊕©©
LOW 6
Topical ant if ungals
may lead to more local
irritat ion events com-
pared to placebo for pa-
t ients with chronic rhi-
nosinusit is
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0.7% 1.5%
(0.4 to 5.6)
0.8%more
(0.3 fewer to 5 more)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HRQL: health-related quality of lif e; MD: mean dif ference; OR: odds rat io; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by two levels due to imprecision: there was some evidence to suggest that the data were skewed in three of the
f ive studies, reducing our conf idence in the results. Furthermore, the validity of some instruments was unclear.
2Downgraded by one level due to inconsistency: the results of the two studies appeared to dif fer f rom each other. Downgraded
by one level due to indirectness: all of the included populat ion had nasal polyps, which may not be representat ive of all chronic
rhinosinusit is pat ients. Downgraded by two levels due to imprecision: the data f rom one study had wide conf idence intervals
and the other study presented only median and interquart ile range (IQR) values.
3Ebbens 2006 measured the symptoms of nasal blockage, rhinorrhoea, facial pain, postnasal drip and anosmia. Weschta
2004 measured the symptoms of nasal blockage, facial pain, smell disturbance, nasal discharge and sneezing.
4Downgraded by two levels due to imprecision: only one trial reported any events (two events in treatment group), result ing in
very wide conf idence intervals. Poor report ing of epistaxis results in the trials.
5Downgraded by one level due to inconsistency: adverse ef fects were generally poorly reported and def init ions were likely
to be dif ferent between studies as the event rates were very dif f erent between studies. Downgraded by two levels due to
imprecision. Only one trial reported any events and the conf idence intervals were very wide.
6Downgraded by two levels due to imprecision: small numbers of events lead to wide conf idence intervals, which include a
clinically important increase and a clinically important decrease in adverse ef fects.
7Downgraded by two levels due to imprecision: results come f rom one study. A minimally important dif f erence has been
ident if ied as three points for the SF-36 and so the conf idence intervals include a potent ially clinically important ef fect.
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B A C K G R O U N D
This review will update and replace a previously published re-
view ’Topical and systemic antifungal therapy for the symptomatic
treatment of chronic rhinosinusitis’ (Sacks 2011).
Description of the condition
Chronic rhinosinusitis is characterised by inflammationof the nose
and paranasal sinuses. It is defined by the presence of two or more
symptoms, one of which must be nasal blockage/obstruction/con-
gestion or nasal discharge (anterior/posterior nasal drip) and one
of facial pain/pressure and/or reduction or loss of sense of smell.
Symptoms must have continued for at least 12 weeks. In addition,
people must have either mucosal changes within the ostiomeatal
complex or sinuses (or both) as evidenced by a computerised to-
mography (CT) scan and/or endoscopic signs of at least one of the
following: nasal polyps, mucopurulent discharge primarily from
the middle meatus or oedema/mucosal obstruction primarily in
the middle meatus (EPOS 2012).
Two major phenotypes of chronic rhinosinusitis have been iden-
tified based on the presence or absence of nasal polyps on ex-
amination. Nasal polyps are tumour-like hyperplastic swellings of
the nasal mucosa, most commonly originating from within the
ostiomeatal complex (Larsen 2004). Chronic rhinosinusitis with
nasal polyps (CRSwNP) is diagnosed when polyps are seen (on
direct or endoscopic examination) bilaterally in the middle mea-
tus. The acronym CRSsNP is used for the condition in which no
polyps are present.
Although the aetiology of chronic rhinosinusitis is not fully un-
derstood, it may involve abnormalities in the host response to ir-
ritants, commensal and pathogenic organisms and allergens, ob-
struction of sinus drainage pathways, abnormalities of normal mu-
cociliary function, loss of the normal mucosal barrier or infection.
Two typical profilesmay be observed with respect to inflammatory
mediators; in eosinophilic chronic rhinosinusitis, which is typi-
cally associated with nasal polyps, high levels of eosinophils, im-
munoglobulin E (IgE) and interleukin (IL)-5 may be found, while
in neutrophilic chronic rhinosinusitis, more often associated with
chronic rhinosinusitis without polyps, neutrophils predominate,
with elevated interferon (IFN) gamma, IL-8 and tumour necrosis
factor (TNF) (EPOS 2012).
While treatment decisions should be made based on an under-
standing of the patient’s chronic rhinosinusitis phenotype and
likely aetiology, in practice treatment may be initiated without
knowledge of the polyp status, particularly in primary care. This
review (and most of its companion reviews) consider patients with
and without polyps together in the initial evaluation of treatment
effects. However, subgroup analyses explore potential differences
between them.
There is much debate regarding the role of fungus in the aetiology
of chronic rhinosinusitis. Intranasal fungus can be demonstrated
in nearly all diseased and normal sinuses (Braun 2003; Lackner
2005; Ponikau 1999). The definition and categorisation of fun-
gal rhinosinusitis is still controversial but the most commonly ac-
cepted system divides the condition into two: invasive and non-
invasive disease, based on histopathological evidence of tissue in-
vasion by fungi (Chakrabarti 2009). Invasive fungal disease is a
unique entity and represents angioinvasive fungal propagation in
the immunocompromised host setting. This is not the common
presentation of chronic rhinosinusitis experienced by the vast ma-
jority of chronic sinusitis patients. Treatments for invasive fungal
sinusitis usually include surgery followed by medical treatment
(EPOS 2012).
Non-invasive fungal rhinosinusitis can be divided into two cate-
gories: a fungus ball (also known as mycetoma) and allergic fungal
rhinosinusitis (AFRS). A fungus ball is a fungal collection in an
abnormal sinus that usually produces only mild symptoms and
can be surgically removed. Patients with fungus balls will not be
included in this review.
AFRS is a well-recognised subgroup of chronic rhinosinusitis, in
which an IgE mediated hypersensitivity to fungal elements drives
the inflammatory process. Allergic fungal rhinosinusitis is gener-
ally diagnosed using the Bent-Kuhn criteria (type I hypersensitiv-
ity confirmed by history, skin tests or serology; nasal polyposis;
characteristic CT scan (double density sign); eosinophilic mucus
without fungal invasion into sinus tissue; positive fungal stain of si-
nus contents removed intraoperatively or during office endoscopy)
(Bent 1994). A more recent derivation of this was proposed by
Philpott et al whereby immunocompetence replaces type I hy-
persensitivity, reflecting the group of characteristic patients seen
in rhinologic practice (Philpott 2011). Following on from this,
there is some evidence that a much broader group of patients with
chronic rhinosinusitis with an eosinophilic inflammation may be
mediated by fungal elements and a subsequent cascade of im-
mune effects through non-classical pathways (Sok 2006). Further-
more, since Bent and Kuhn defined their subgroup of AFRS, fur-
ther parallel groups have been defined including eosinophilic fun-
gal rhinosinusitis (EFRS) and eosinophilic mucinous rhinosinusi-
tis (EMRS). Patients with eosinophilic fungal rhinosinusitis have
been defined as those who meet the Bent-Kuhn criteria for AFRS
except for the IgE mediated hypersensitivity to a fungal allergen.
Patients with eosinophilic mucinous rhinosinusitis are defined as
those who meet the Bent-Kuhn criteria for AFRS except that they
have no positive fungal culture or smear.
Chronic rhinosinusitis represents a common source of ill health;
11% of UK adults reported chronic rhinosinusitis symptoms in a
worldwide population study (Hastan 2011). Symptomshave ama-
jor impact on quality of life, reportedly greater in several domains
of the SF-36 than angina or chronic respiratory disease (Erskine
2015; Gliklich 1995). Acute exacerbations, inadequate symptom
control and respiratory disease exacerbation are common.Compli-
cations are rare, but may include visual impairment, bone erosion
and expansion, and intracranial infection (EPOS 2012). Chronic
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rhinosinusitis affects an increasing proportion of the adult popu-
lation until the sixth decade of life and then declines (Chen 2003).
The most commonly used interventions for chronic rhinosinusi-
tis are used either topically (sprayed into the nose) or systemi-
cally (by mouth) and include steroids, antibiotics and saline. In
the late 1990s some centres advocated the use of topical antifun-
gals in chronic rhinosinusitis patients (Ponikau 1999). Since then
there has been increasing controversy and contrasting papers have
both advocated and refuted the use of both topical and systemic
antifungal agents in the management of these patients (Ebbens
2007). A carefully defined population of patients with AFRS (and
its derivatives) is likely to benefit most from the use of antifungals,
however trials specifically in this group have been less prevalent.
Description of the intervention
Antifungal agents can be used as systemic medications (orally or
intravenously) or as topical preparations delivered directly to the
nose and sinuses. Topical treatments can be given using different
delivery systems such as douching, nebulisation, atomisation, in-
halation, irrigation, spray, drops or powder insufflations.
We will include all antifungals used in the management of inflam-
matory disease of the paranasal sinuses, both systemic and topical.
Examples of antifungal agents include amphotericin B, glucona-
zole, itraconazole, voriconazole and ketoconazole. These agents
may be fungistatic or fungicidal depending on the drug concen-
tration and the susceptibility of the fungus.
How the intervention might work
Antifungal agents work in one of two ways, either as fungicides
that kill the fungal spores, or as fungistatics that inhibit the growth
and reproduction of the spores. Although good research demon-
strates an interaction of the immune systemwith fungus in chronic
rhinosinusitis (Ponikau 2007), this does not necessarily imply that
fungus is the key aetiological factor and that antifungals will thus
be effective in managing the disease. In chronic rhinosinusitis it
may be that inappropriate immune activation may be the driving
pathologic mechanism and fungal elements are only the innocent
target of the process. Fungus is commonly found in our environ-
ment and thus freely available to inhale into the nose (Lackner
2005).
When taken orally (systemic) certain classes of antifungals, such
as the azoles, have the potential for adverse effects such as gas-
trointestinal disturbances and they have also been associated with
serious adverse effects, particularly with regard to hepatic and re-
nal toxicity. Topical amphotericin is expensive and also associated
with potential adverse effects such as headache and local irritations
(Ebbens 2006).
Why it is important to do this review
The previous Cochrane Review and other more recent systematic
reviews have concluded that there is no convincing evidence to
support the use of antifungals in chronic rhinosinusitis (Mistry
2014; Sacks 2011). However, the authors of these reviews have
commented on the clinical diversity of the included populations
within the trials, particularly with regard to diagnosis. Often the
population includes patients with both chronic rhinosinusitis and
AFRS, as this distinction is ambiguous in some trials. It is impor-
tant to understand whether there is a difference in treatment effect
between these two populations. Similarly, the existing reviews in-
clude a heterogeneous population of people with respect to sinus
surgery prior to the start of the trial.
We will not include studies designed to evaluate interventions in
the immediate peri-surgical period, which are focused on assess-
ing the impact of the intervention on the surgical procedure or
on modifying the post-surgical results (preventing recurrence of
chronic rhinosinusitis symptoms).
This review is one of a suite of Cochrane Reviews looking at com-
monmanagement options for patients with chronic rhinosinusitis
(Chong 2016a; Chong 2016b; Chong 2016c; Head 2016a; Head
2016b; Head 2016c), and we have used the same methods and
outcome measures as have been used across these reviews.
This systematic review will aim to look at the balance of benefits
and harms for both systemic and topical antifungal agents in the
treatment of patients with chronic rhinosinusitis.
O B J E C T I V E S
To assess the effects of systemic and topical antifungal agents in
patients with chronic rhinosinusitis, including those with allergic
fungal rhinosinusitis (AFRS) and, if possible, AFRS exclusively.
The review excludes patients in the immediate post-surgical period
(within six weeks of sinus surgery).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
trials and quasi-randomised trials (cross-over trials were only
included if the data from the first phase were available); and
• patients were followed up for at least two weeks.
We excluded studies with the following design characteristics:
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• randomised patients by side of nose (within-patient
controlled) because it is difficult to ensure that the effects of any
of the interventions considered can be localised; or
• perioperative studies, where the sole purpose of the study
was to investigate the effect of the intervention on surgical
outcome.
Types of participants
Patients (adults and children) with chronic rhinosinusitis, whether
with polyps or without polyps. This included the subgroups of
people with a diagnosis of allergic fungal rhinosinusitis (AFRS),
eosinophilic fungal rhinosinusitis (EFRS) or eosinophilic muci-
nous rhinosinusitis (EMRS).
We excluded studies that included a majority of patients with:
• cystic fibrosis;
• aspirin-exacerbated respiratory disease (aka Samter’s triad);
• antrochoanal polyps (benign polyps originating from the
mucosa of the maxillary sinus);
• malignant polyps and inverted papilloma;
• primary ciliary dyskinesia;
• invasive fungal disease in the sinuses;
• fungal balls (sinus mycelia);
• a history of surgery for nasal polyps within six weeks of
entry to the study.
Fungus can be demonstrated in almost all diseased and normal
sinuses (Lackner 2005), thus we did not set associated fungus con-
firmed either histologically or on culture as an inclusion criterion.
The immunological role of the fungus and the host is still an area
of ongoing research.
Patients with chronic rhinosinusitis were included if they fulfilled
the criteria defined by EPOS (EPOS 2012).
In order to identify patients with AFRS/EFRS for subgroup anal-
ysis, we used the modified Bent-Kuhn criteria (Philpott 2011),
where a patient must fulfil the following criteria:
• type I hypersensitivity for fungal spore(s) confirmed by
history, skin tests or serology OR immunocompetence;
• nasal polyposis;
• characteristic CT scan (double density sign);
• eosinophilic mucus without fungal invasion into sinus
tissue;
• positive fungal stain of sinus contents removed
intraoperatively or during office endoscopy.
We identified patients with EMRS for subgroup analysis if they
met the criteria for AFRS (above) except that they did not have a
positive fungal culture/smear.
Types of interventions
We included the following groups of topical or systemic antifun-
gals:
• polyene antifungals (e.g. amphotericin);
• imidazole, triazole and thiazole antifungals (e.g.
itraconazole);
• allylamines;
• echinocandins.
We included both topically applied and systemic antifungals in the
review.We included any dose and deliverymethod. Theminimum
duration of treatment was 28 days.
Comparisons
The comparators were:
• placebo or no intervention;
• another class of antifungals;
• the same type of antifungal, which is either:
◦ given for a different duration;
◦ given at a different dose;
• other treatments for chronic rhinosinusitis, including:
◦ intranasal corticosteroids;
◦ oral/systemic steroids;
◦ antibiotics;
◦ nasal saline irrigation.
Concurrent treatments were allowed if they were used in both
treatment arms; they included, for example:
• nasal saline irrigation only;
• intranasal corticosteroids only;
• intranasal corticosteroids plus antibiotics;
• intranasal corticosteroids plus nasal irrigation plus oral
steroids;
• other combinations.
Comparison pairs
There were multiple possible comparison pairs due to the large
number of interventions allowed.
The main comparison pairs of interest were:
• topical antifungalsversus no antifungal intervention or
placebo;
• systemic antifungals versus no antifungal intervention or
placebo;
• topical antifungals versus no intervention or placebo
alongside intranasal steroids or other standard treatment in all
arms of the trial.
Other possible comparison pairs were:
• antifungals versus intranasal steroids;
• antifungals versus oral/systemic steroids;
• antifungals class A versus antifungals class B;
• antifungal A with duration of treatment X versus antifungal
A with duration of treatment Y;
• antifungal A at dose X versus antifungal A at dose Y.
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Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
Primary outcomes
• Health-related quality of life, using disease-specific health-
related quality of life scores, such as the Sino-Nasal Outcome
Test-22 (SNOT-22), Rhinosinusitis Outcome Measures-31
(RSOM-31) and SNOT-20.
• Disease severity, as measured by patient-reported symptom
score (such as the Chronic Sinusitis Survey (CSS) questionnaire
and visual analogue scales). In the absence of validated symptom
score data, patient-reported individual symptom scores were
reported for the following symptoms: nasal obstruction/
blockage/congestion, nasal discharge (rhinorrhoea), facial
pressure/pain, loss of sense of smell (adults) and cough (children).
• Significant adverse effects: hepatic toxicity (systemic
antifungals).
Secondary outcomes
• Health-related quality of life, using generic quality of life
scores, such as the SF-36, EQ-5D and other well-validated
instruments.
• Other adverse effects: gastrointestinal disturbances, allergic
reactions (systemic antifungals).
• Other adverse effects: epistaxis, headache, local discomfort
(e.g. itching, mild burning) (topical antifungals).
• Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Mackay/Lund-
Kennedy).
• Computerised tomography (CT) scan score (e.g. Lund-
Mackay).
Both short-term (at the end of treatment) and long-term effects are
important therefore we evaluated outcomes at the end of treatment
or within four weeks, at four weeks to sixmonths, six to 12months
and more than 12 months. For adverse effects we analysed data
from the longest time periods.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 17 November 2017.
Electronic searches
The Information Specialist searched for published, unpublished
and ongoing studies by running searches in the following databases
from their inception:
• the Cochran ENT Trials Register (searched via the
Cochrane Register of Studies 17 November 2017);
• the Cochrane Register of Studies Online (searched 17
November 2017);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) (1946 to 20 November 2017);
• Ovid Embase (1974 to 20 November 2017);
• Ovid CAB Abstracts (1910 to 20 November 2017);
• EBSCO CINAHL (1982 to 20 November 2017);
• LILACS, lilacs.bvsalud.org (searched 20 November 2017);
• KoreaMed (searched via Google Scholar 20 November
2017);
• IndMed, www.indmed.nic.in (searched 20 November
2017);
• PakMediNet, www.pakmedinet.com (searched 20
November 2017);
• Web of Knowledge, Web of Science (1945 to 20 November
2017);
• ClinicalTrials.gov, (searched via the Cochrane Register of
Studies and ClinicalTrials.gov 21 November 2017);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
20 November 2017);
• ISRCTN, www.isrctn.com (searched 20 November 2017).
The subject strategies for databases were modelled on the search
strategy designed for CENTRAL (Appendix 1). Where appropri-
ate, these were combined with subject strategy adaptations of the
highly sensitive search strategy designed by Cochrane for iden-
tifying randomised controlled trials and controlled clinical trials
(as described in the Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011)).
Searching other resources
We scanned the reference lists of identified publications for ad-
ditional trials and contacted trial authors where necessary. In
addition, the Information Specialist searched Ovid MEDLINE,
theCochrane Library and Google to retrieve existing systematic re-
views relevant to this systematic review, so that we could scan their
reference lists for additional trials. The Information Specialist also
ran non-systematic searches of Google Scholar to retrieve grey lit-
erature and other sources of potential trials.
Data collection and analysis
Selection of studies
At least two review authors (KH, LYC, SS) independently screened
all titles and abstracts of the studies obtained from the database
searches to identify potentially relevant studies. At least two review
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authors (KH, LYC, CP, CH) evaluated the full text of each po-
tentially relevant study to determine whether it met the inclusion
and exclusion criteria for this review.
We resolved any differences by discussion and consensus, with
the involvement of a third author for clinical and methodological
input where necessary.
Data extraction and management
At least two review authors (KH, SS, LYC) independently ex-
tracted data from each study using a standardised data collection
form (see Appendix 2).Whenever a study hadmore than one pub-
lication, we retrieved all publications to ensure complete extrac-
tion of data. Where there were discrepancies in the data extracted
by different review authors, we checked these against the original
reports and resolved differences by discussion and consensus, with
the involvement of a third author or a methodologist where ap-
propriate.We contacted the original study authors for clarification
or for missing data. If we had found differences between publica-
tions of a study, we would have contacted the original authors for
clarification. We would have used data from the main paper(s) if
no further information was found.
We included key characteristics of the studies, such as study design,
setting, sample size, population and how outcomes were defined
or collected in the studies. In addition, we also collected baseline
information on prognostic factors or effect modifiers. For this
review, this included:
• presence or absence of allergic fungal rhinosinusitis (AFRS),
eosinophilic fungal rhinosinusitis (EFRS) and eosinophilic
mucinous rhinosinusitis (EMRS);
• presence or absence of nasal polyps and baseline nasal polyp
score where appropriate;
• presence of eosinophilic chronic rhinosinusitis;
• whether the patient has had previous sinus surgery.
We also noted down whether studies only selected patients with
known AFRS and how this was identified.
For the outcomes of interest to the review, we extracted the find-
ings of the studies on an available case analysis basis; i.e. we in-
cluded data from all patients available at the time points based on
the treatment randomised whenever possible, irrespective of com-
pliance or whether patients had received the treatment as planned.
In addition to extracting pre-specified information about study
characteristics and aspects of methodology relevant to risk of bias,
we extracted the following summary statistics for each trial and
each outcome:
• For continuous data: the mean values, standard deviations
and number of patients for each treatment group. Where
endpoint data were not available, we extracted the values for
change from baseline. We analysed data from measurement
scales such as SNOT-22 and EQ-5D as continuous data.
• For binary data: the numbers of participants experiencing
an event and the number of patients assessed at the time point.
• For ordinal scale data: if the data appeared to be
approximately normally distributed or if the analysis that the
investigators performed suggested parametric tests were
appropriate, then we treated the outcome measures as
continuous data. Alternatively, if data were available, we
converted into binary data.
We prespecified the time points of interest for the outcomes in
this review. While studies may have reported data at multiple time
points, we only extracted the longest available data within the time
points of interest. For example, for ’short’ follow-up periods, our
time point is defined as ’three to six months’ post-randomisation.
If a study reported data at three, four and six months, we only
extracted and analysed the data for the six-month follow-up.
Extracting data from figures
Where values for primary or secondary outcomes were shown as
figures within the paper we contacted the study authors to try to
obtain the raw values. When the raw values were not provided,
we extracted information from the graphs using an online data ex-
traction tool (http://arohatgi.info/WebPlotDigitizer/app/), using
the best quality version of the relevant figures available.
Assessment of risk of bias in included studies
At least two review authors (KH, SS, LYC) independently assessed
the risk of bias of each included study. We followed the guidance
in the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), and we used the Cochrane ’Risk of bias’ tool.
With this tool we assessed the risk of bias as ’low’, ’high’ or ’unclear’
for each of the following six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessment;
• incomplete outcome data;
• selective reporting;
• other sources of bias.
Measures of treatment effect
We summarised the effects for dichotomous outcomes (e.g. pro-
portion of patients with symptom resolution) as risk ratios (RR)
with confidence intervals (CIs). For the key outcomes that we pre-
sented in the ’Summary of findings’ table, we also expressed the
results as absolute numbers based on the pooled results and com-
pared to the assumed risk. We also planned to calculate the num-
ber needed to treat to benefit (NNTB) using the pooled results.
The assumed baseline risk will typically be either (a) the median of
the risks of the control groups in the included studies, this being
used to represent a ’medium risk population’ or, alternatively, (b)
the average risk of the control groups in the included studies is
used as the ’study population’ (Handbook 2011). If a large number
of studies had been available, and where appropriate, we had also
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planned to present additional data based on the assumed baseline
risk in (c) a low-risk population and (d) a high-risk population.
For continuous outcomes, we expressed treatment effects as amean
difference (MD) with standard deviation (SD). If different scales
were used to measure the same outcome we used the standardised
mean difference (SMD), and we provided a clinical interpretation
of the SMD values.
Unit of analysis issues
This review did not use data from phase II of cross-over studies or
from studies where the patient was not the unit of randomisation,
i.e. studies where the side (right versus left) was randomised.
If we had found cluster-randomised trials, we planned to analyse
these according to the methods in section 16.3.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011).
Dealing with missing data
We contacted study authors via email whenever the outcome of
interest was not reported, if the methods of the study suggested
that the outcome had been measured. We did the same if not all
data required for meta-analysis were reported, unless the missing
data were standard deviations. If standard deviation data were not
available, we approximated these using the standard estimation
methods from P values, standard errors or 95% CIs if these were
reported, as detailed in the Cochrane Handbook for Systematic Re-
views of Interventions (Handbook 2011). Where it was impossible
to estimate these, we contacted the study authors.
Apart from imputations for missing standard deviations, the only
other imputations that we had planned were calculations relating
to disease severity (measured by patient-reported symptom scores)
as we thought that some studies may have measured individual
symptoms rather than using validated instruments (see ’Imputing
total symptom scores’ below). We extracted and analysed data for
all outcomes using the available case analysis method.
Imputing total symptom scores
Where a paper did not present information for the total disease
severity in terms of patient-reported symptom scores but presented
data for the results of individual symptoms,wewould have used the
symptoms covering the important domains of the EPOS chronic
rhinosinusitis diagnosis criteria (EPOS 2012), in order to calculate
a total symptom score. The EPOS 2012 criteria for chronic rhi-
nosinusitis require at least two symptoms. One of the symptoms
must be either nasal blockage or nasal discharge; other symptoms
can include facial pressure/pain, loss of sense of smell (for adults)
or cough (for children). Where mean final values or changes from
baseline were presented in the paper for the individual symptoms
we would have sum these to calculate a ’total symptom score’. We
would have calculated standard deviations for the total symptom
score as if the symptoms were independent, random variables that
were normally distributed. We acknowledge that there would have
been likely to be a degree of correlation between the individual
symptoms, however we would have used this process as the mag-
nitude of correlation between the individual symptoms is not cur-
rently well understood (no evidence found). If the correlation is
high, the summation of variables as discrete variables is likely to
give a conservative estimate of the total variance of the summed
final score. If the correlation is low, this method of calculation will
underestimate the standard deviation of the total score. However,
the average patient-reported symptom scores have a correlation
coefficient of about 0.5; if this is also applicable to chronic rhinos-
inusitis symptoms, themethod used should have hadminimal im-
pact (Balk 2012). As this method of calculation does not take into
account weighting of different symptoms (no evidence found),
we would have downgraded all the disease severity outcomes in
GRADE for lack of use of validated scales.
Assessment of heterogeneity
We assessed clinical heterogeneity (which may be present even
in the absence of statistical heterogeneity) by examining the in-
cluded trials for potential differences between studies in the types
of participants recruited, interventions or controls used and the
outcomes measured.
We assessed statistical heterogeneity by visually inspecting the for-
est plots and by considering the Chi² test (with a significance level
set at P value < 0.10) and the I² statistic, which calculates the
percentage of variability that is due to heterogeneity rather than
chance, with I² values over 50% suggesting substantial heterogene-
ity (Handbook 2011).
Assessment of reporting biases
We assessed reporting bias as between-study publication bias and
within-study outcome reporting bias.
Outcome reporting bias (within-study reporting bias)
We assessed within-study reporting bias by comparing the out-
comes reported in the published report against the study protocol,
whenever this could be obtained. If the protocol was not available,
we compared the outcomes reported to those listed in themethods
section. If results were mentioned but not reported adequately in a
way that allowed analysis (e.g. the report only mentioned whether
the results were statistically significant or not), bias in a meta-anal-
ysis is likely to occur. We tried to find further information from
the study authors. If no further information could be obtained, we
noted this as being a high risk of bias. Where there was insufficient
information to judge the risk of bias, we noted this as an unclear
risk of bias (Handbook 2011).
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Publication bias (between-study reporting bias)
We planned to create a funnel plot if sufficient studies (more than
10) were available for an outcome. If we had observed asymmetry
of the funnel plot, we would have conducted more formal inves-
tigation using the methods proposed by Egger 1997.
Data synthesis
We conducted all meta-analyses using Review Manager 5.3
(RevMan 2014). For dichotomous data, we analysed treatment
differences as a risk ratio (RR) calculated using the Mantel-Haen-
szel method. If we had found time-to-event data we had planned
to analyse it using the generic inverse variance method.
If we had found continuous data from different studies that were
suitable for meta-analysis, and if all the data were from the same
scale, we would have pooled mean values obtained at follow-up
with change outcomes and reported this as a MD. However, if
the data were from different scales, we would have used the SMD
as an effect measure and we would not have pooled change and
endpoint data.
When statistical heterogeneity is low, random-effects versus fixed-
effect methods yield trivial differences in treatment effects. How-
ever, when statistical heterogeneity is high, the random-effects
method provides a more conservative estimate of the difference.
Subgroup analysis and investigation of heterogeneity
We planned to conduct some subgroup analyses regardless of
whether statistical heterogeneity was observed, as these are widely
suspected to be potential effect modifiers. For this review, this in-
cluded:
• Presence of allergic fungal rhinosinusitis (as defined by the
modified Bent-Kuhn criteria; see Types of participants), EFRS
and EMRS. Patients with AFRS may respond differently to
antifungal agents as in AFRS an IgE mediated hypersensitivity to
fungal elements drives the inflammatory process.
• Phenotype of patients: whether patients have chronic
rhinosinusitis without nasal polyps, chronic rhinosinusitis with
nasal polyps, they are a mixed group or the status of polyps is not
known or not reported. We planned to undertake the subgroup
analysis as although there appears to be a considerable overlap
between the two forms of chronic rhinosinusitis with regards to
inflammatory profile, clinical presentation and effect of
treatment (Cho 2012; DeMarcantonio 2011; Ebbens 2010;
Fokkens 2007; Ragab 2004; Ragab 2010; van Drunen 2009),
there is some evidence pointing to differences in the respective
inflammatory profiles (Kern 2008; Keswani 2012; Tan 2011;
Tomassen 2011; Zhang 2008; Zhang 2009), and potentially
even differences in treatment outcome (Ebbens 2011). The role
of fungi in the pathology is also unclear and this makes it
uncertain whether antifungals will have similar effects.
• Eosinophilic versus non-eosinophilic chronic rhinosinusitis.
Some researchers hypothesise that patients with eosinophilic
chronic rhinosinusitis will form an eosinophilic reaction towards
the fungi present in their sinonasal mucin. It is proposed that
this reaction will subsequently be involved in the inflammatory
response (Ponikau 1999).
We planned to present the main analyses of this review according
to the subgroup of presence of AFRS. We intended to present all
other subgroup analysis results in tables.
When studies had amixed group of patients, we planned to analyse
the study as one of the subgroups (rather than as a mixed group) if
more than 80% of patients belonged to one category. For example,
if 81% of patients had AFRS, we would have analysed the study
as that subgroup.
In addition to the subgroups above, we planned to conduct the
following subgroup analyses in the presence of statistical hetero-
geneity:
• patient age (children versus adults);
• dose;
• duration of treatment;
• method of delivery;
• class of antifungal agent.
Sensitivity analysis
We planned to carry out sensitivity analyses to determine whether
the findings were robust to the decisions made in the course of
identifying, screening and analysing the trials. We planned to con-
duct sensitivity analysis for the following factors, whenever possi-
ble:
• impact of model chosen: fixed-effect versus random-effects
model;
• risk of bias of included studies: excluding studies with high
risk of bias (we defined these as studies that had a high risk of
allocation concealment bias and a high risk of attrition bias
(overall loss to follow-up of 20%, differential follow-up
observed));
• how outcomes were measured: we planned to investigate
the impact of including data where the validity of the
measurement was unclear.
If any of these investigations found a difference in the size of
the effect or heterogeneity, we would have mentioned this in the
Effects of interventions section.
GRADE and ’Summary of findings’ table
Using theGRADE approach, at least two review authors ( KH, SS,
LYC) independently rated the overall quality of evidence using the
GDT tool ( http://www.guidelinedevelopment.org/) for themain
comparison pairs listed in the Types of interventions section. The
quality of evidence reflects the extent to which we are confident
that an estimate of effect is correct and we will apply this in the
interpretation of results. There are four possible ratings: ’high’,
’moderate’, ’low’ and ’very low’. A rating of ’high’ quality evidence
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implies that we are confident in our estimate of effect and that
further research is very unlikely to change our confidence in the
estimate of effect. A rating of ’very low’ quality implies that any
estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
The ’Summary of findings’ tables present only the top priority out-
comes (disease-specific health-related quality of life, disease sever-
ity score, adverse effects and generic quality of life score). We did
not include the outcomes endoscopic score or CT scan score in
the ’Summary of findings’ tables.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 1496 references after removal
of duplicates. We identified two additional references from other
sources. We screened the titles and abstracts and subsequently
removed 1413 references. We assessed 85 full texts for eligibility.
We excluded 65 references, 38 without presenting reasons. Most
of these studies were the wrong study design (literature review,
systematic review, letter). We excluded 23 studies (27 records),
with reasons (see Excluded studies).
We included eight studies (15 references) (see Included studies).
We did not identify any ongoing studies.
There are four studies (five references) awaiting assessment (Deka
2007; Frigas 2007; Lopatin 2004; Stergiou 2007). These are pre-
sented only as abstracts and although we attempted to contact the
authors to determine if the trial was published in full, no response
was received.
We did not identify any ongoing studies.
A flow chart of study retrieval and selection is provided in Figure
1.
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Figure 1. Study flow diagram.
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Included studies
We included eight studies in the review. More details about the
included studies canbe found inCharacteristics of included studies
and a summary can be found Table 1.
Design
All of the included studies were parallel-group randomised con-
trolled trials (RCTs). Six studies had two study arms, one study
had three study arms (Shin 2004) and one study had four study
arms (Corradini 2006), although in each case only two arms were
relevant to this review. Six of the studies blinded participants
and healthcare professionals to treatment group (Ebbens 2006;
Hashemian 2016; Kennedy 2005; Liang 2008; Ponikau 2005;
Weschta 2004).
Sample size
There were 490 participants relevant to this review in the included
studies. The sample sizes in the studies ranged from 30 to 116
participants. Only one study included more than 80 participants.
Setting
Seven of the studies were single-centre, conducted in six countries:
two from the USA and one each from Germany, Iran, Italy, South
Korea and Taiwan. One study was multi-centre and conducted at
six sites in four countries (Belgium, the Netherlands, Spain and
the UK) (Ebbens 2006). The settings of all studies were secondary
or tertiary ear, nose and throat (ENT) clinics.
Population
Age
Six studies only included adults (aged 18 years or older), one study
included participants from the age of 12 years (Liang 2008), and
one study did not provide any information on the age of partici-
pants (Corradini 2006). In the seven studies providing informa-
tion, the mean ages of participants ranged from 39 to 53 years.
No studies included children under 12 years.
Sex
Seven studies provided details of the sex of participants and all
included males and females. The percentage of male participants
in the studies ranged from 33.6% to 70.8%. Corradini 2006 did
not provide any information on the sex of participants.
Diagnosis
One study includedpatientswith nasal polyps and apositive fungal
culture but did not mention a formal diagnosis of chronic rhinos-
inusitis (Corradini 2006). All remaining studies included patients
with chronic rhinosinusitis diagnosed using appropriate meth-
ods. Three studies included participants who were unresponsive to
previous medical therapy for chronic rhinosinusitis (Hashemian
2016; Kennedy 2005; Ponikau 2005). All participants in two stud-
ies (Corradini 2006; Ponikau 2005) and 77% of participants in
Weschta 2004 had an initial fungal culture at the start of the trial.
This was not measured in the other studies.
Nasal polyps
Two studies did not provide details about whether participants
had polyps (Kennedy 2005; Ponikau 2005), three studies used
nasal polyps as an inclusion criterion (Corradini 2006; Shin 2004;
Weschta 2004), and one study excluded patients with nasal polyps
(Liang 2008). The remaining two studies reported polyps in
43.8% (Hashemian 2016) and 81.9% (Ebbens 2006) of partici-
pants.
Allergic fungal rhinosinusitis (AFRS)
Four studies excluded patients with AFRS (Corradini 2006;
Ebbens 2006; Shin 2004; Weschta 2004). The other studies did
not report whether patients were diagnosed with AFRS.
Intervention
Topical antifungals
Seven studies investigated the use of topical antifungal agents: am-
photericin B (six studies) and fluconazole (one study). A range of
different delivery methods, concentrations, frequencies and dura-
tions were used in the studies and further details can be found in
Table 1. It was noticeable that the daily doses of topical antifungal
used in the studies were generally lower than would be expected.
Whilst there is no formal guidance for topical use (such as in the
British National Formulary; BNF 2018), rhinology clinical prac-
tice dose regimens for amphotericin B would be approximately 20
mg per day. Of the six studies using this agent, four used 10 mg/
day or less, so half of the ’usual’ daily dose or less.
Systemic antifungals
Kennedy 2005 (53 participants) used systemic terbinafine tablets
(625 mg/day) for six weeks, which is considered to be a high daily
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dose. For reference, the British National Formulary recommends a
dose of 250 mg/day for terbinafine (BNF 2018).
Use of adjuvant treatments
Intranasal corticosteroids were used routinely in one study (
Hashemian 2016), and the current treatment regimen was contin-
ued in three studies (Ebbens 2006; Kennedy 2005; Ponikau 2005;
Weschta 2004). Adjuvant treatments were not allowed in Liang
2008 and not reported in another study (Shin 2004). All partici-
pants in Corradini 2006 underwent a medical polypectomy with
40 mg triamcinolone retard intramuscularly three times every 10
days (total dose 120 mg) and continued with lysine acetylsalicylate
(4 mg/day; six times/week). Further details are provided in Table
1.
Comparison
All included studies compared the effects of topical antifungals
(seven studies; 437 participants) or systemic antifungals (one
study, 53 participants) with placebo or no treatment.
Topical antifungals compared with placebo or no treatment
Six studies compared topical antifungals to placebo solution
(Ebbens 2006;Hashemian 2016; Liang 2008; Ponikau 2005; Shin
2004; Weschta 2004). Corradini 2006 compared topical antifun-
gal agents with no treatment.
Systemic antifungals compared with placebo or no treatment
One study (53 participants) compared terbinafine tablets with
placebo tablets (Kennedy 2005).
Outcomes
Neither Corradini 2006 nor Shin 2004 presented any primary or
secondary efficacy outcomes as defined for this review, with the
former reporting polyps recurrence at 20 months and the latter
investigating the cytokine protein content of nasal polyps. The
adverse effects results from these studies are included in the review,
however.
Primary outcomes
Disease-specific health-related quality of life
Five studies presented this information, using three different scales.
Details of the range and direction of the instruments are provided
in Table 2.
• Rhino-sinusitis Disability Index (RSDI): Kennedy 2005
(nine weeks).
• Sino-Nasal Outcomes Test (SNOT-20): Ponikau 2005
(three and six months); Hashemian 2016 (eight weeks; it is
unclear whether a Persian/Iranian version was used or what the
impact of this was on validation).
• Rhinosinusitis Outcome Measure-31 (RSOM-31): Ebbens
2006 (13 weeks); Liang 2008 (two and four weeks; Chinese
version).
Weschta 2004 used a “rhinosinusitis quality of life” score (RQL)
but as we could find no details on whether this instrument had
undergone any validation, we did not include the results.
Disease severity
Three studies presented information on disease severity:
• Patient’s overall evaluation of sinusitis measured on a four-
point scale (although the authors did not provide information on
whether higher or lower scores indicated worse symptoms)
(Kennedy 2005).
• Sum of the following individual symptoms each measured
on a visual analogue scale (VAS) of 0 to 10 cm (higher score =
worse symptoms): nasal blockage, facial pain, smell disturbance,
nasal discharge and sneezing. The sum of individual symptom
values was calculated, with a final range of 0 to 50 (Weschta
2004).
• Sum of the following individual symptoms each measured
on a VAS of 0 to 10 cm (reported as a range of 0 to 100; higher
score = worse symptoms): nasal blockage, rhinorrhoea, facial
pain, postnasal drip and anosmia (loss of sense of smell). The
sum of individual symptom values was calculated, with a final
range of 0 to 500 (Ebbens 2006).
Significant adverse effects: hepatic toxicity (systemic
antifungals)
Kennedy 2005, the only study that investigated systemic antifun-
gal agents, measured the number of patients with increased as-
partate aminotransferase (AST), alanine aminotransferase (ALT)
or gamma-glutamyl (GGT) levels although no definition of ’in-
creased’ was provided.
Secondary outcomes
Generic health-related quality of life
Only Ebbens 2006 measured generic health-related quality of life.
They used the short form-36 (SF-36) questionnaire and separated
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the results into the physical and mental component scores (range
= 0 to 100, lower score = worse quality of life).
Other adverse effects: gastrointestinal disturbances, allergic
reactions (systemic antifungals)
This was reported in Kennedy 2005, the only study investigating
systemic antifungals.
Other adverse effects: epistaxis, headache, local discomfort
(e.g. itching, mild burning) (topical antifungals)
Five of the six studies investigating topical antifungals reported
other adverse effects such as epistaxis, headache and local discom-
fort (Ebbens 2006; Hashemian 2016; Ponikau 2005; Shin 2004;
Weschta 2004).
Endoscopic score (nasal polyps size score or endoscopy score,
e.g. Lund-Kennedy)
Five studies reported the results of nasal endoscopy. Three studies
assessed the extent of nasal polyps:
• Scored each nostril on a scale of 0 to 4 (0 = no polyps, 4 =
polypoid changes below the lower edge of the inferior turbinate);
total range = 0 to 8 (Hashemian 2016; Ponikau 2005).
• Scored each nostril on a scale of 0 to 3 (0 = no polyps; 3 =
polyps fill whole nasal cavity); total range = 0 to 6 (Weschta
2004).
Two studies provided a more general endoscopic score:
• Amount of mucosal disease measured by nasal secretions,
nasal polyps and nasal crusting, each on a scale of 0 to 2 (0 =
absent, 2 = severe) in predefined areas (e.g. middle meatus,
ethmoid region). Sum scores were calculated by adding all
independent values for both nostrils but the total possible range
was not given (Ebbens 2006).
• Measured oedema, discharge, polyps, crusting and scarring,
graded from 0 (normal) to 2 (severely diseased); total range = 0
to 10 (Liang 2008).
Computerised tomography (CT) scan score (e.g. Lund-
Mackay)
Four studies measured CT score using five different measures; two
investigated the percentage change in opacification and three used
variations of the Lund-Mackay score:
Change in opacification:
• Percentage change from baseline in CT opacification score
(Kennedy 2005).
• Percentage change from baseline in inflammatory mucosal
thickening, which occluded the nasal and paranasal cavities
(Ponikau 2005).
Three studies used modified versions of the Lund-Mackay scoring
system:
• Each of the five major left and right sinuses were scored on
a six-point opacification scale (0 = no opacification; 5 = total
opacification; total range of 0 to 50) (Kennedy 2005).
• Each sinus, nasal passage and both osteomeatal complexes
were assessed for mucosal thickening on a four-point scale (0 to
3; 0 = lower severity; total range of 0 to 30) (Hashemian 2016).
• Each of the five major left and right sinuses were scored on
a five-point opacification scale (0 = no opacification, 4 =
complete opacification; total range of 0 to 40) (Weschta 2004).
None of the studies using modified scores refer to validation pa-
pers.
Excluded studies
We excluded 23 studies (27 records), with reasons. See
Characteristics of excluded studies for more details.
We excluded 13 studies (16 papers) because although they were
randomised controlled trials (RCTs) all of the participants under-
went surgery either before or during the trial (Gerlinger 2009;
Gupta 2007; IRCT138706101138N1; Jiang 2015; Khalil 2011;
Lopatin 2007; NCT02285283; Nikakhlagh 2015; Panda 2012;
Ravikumar 2011; Rojita 2017; Somu 2015; Zhang 2012). One
study gave antifungals pre-operatively but the control group un-
derwent surgery immediately and no pre-operative results were
available (Verma 2016).
We excluded eight studies (nine papers) due to the study design:
six were case series where all participants received an antifungal
agent (Chan 2008;Hashemi 2014;Helbling 2006;Hofman 2004;
Joshi 2007; Ricchetti 2002b); one study (two papers) related to a
non-randomised trial comparing an antifungal agent with placebo
(Ricchetti 2002); and one study randomised participants by side
of nose (Thamboo 2011).
We excluded one study as the participants were randomised to
antifungal agents or endoscopic surgery (Patro 2015).
Risk of bias in included studies
See Figure 2 for the ’Risk of bias’ graph (our judgements about
each risk of bias item presented as percentages across all included
studies) and Figure 3 for the ’Risk of bias’ summary.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
20Topical and systemic antifungal therapy for chronic rhinosinusitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Sequence generation
We rated one study as having a high risk of selection bias as it was
unclear from a statement in the paper whether the participants
were randomly selected to the study or randomly allocated to
treatment group (Shin 2004). Two studies stated that the patients
were ’randomly’ allocated to treatment group but provided no
details on the methods used (Corradini 2006; Liang 2008). All
other studies were at low risk of bias for sequence generation.
Allocation concealment
Four studies did not mention any methods used to ensure that the
allocation of patients to treatment groups was not unduly influ-
enced (Corradini 2006; Liang 2008; Shin 2004; Weschta 2004).
All other studies reported methods for ensuring allocation con-
cealment, which included automated randomisation, no knowl-
edge of block size and allocation by someone independent to the
study.
Blinding
Performance bias
Two studies did not mention blinding and so we judged them
to be at high risk of bias for this domain (Corradini 2006; Shin
2004); however, one of these did have a control arm that used
an ’inert’ solution (Shin 2004). All of the remaining studies were
blinded and we judged them to be at low risk of bias.
Detection bias
Similar to performance bias we assessed the same two studies to
be at high risk of detection bias (Corradini 2006; Shin 2004). We
judged the other studies to be at low risk of bias.
Incomplete outcome data
We assessed two studies to be at high risk of attrition bias. Ponikau
2005 reported that 20% of patients (6/30) did not complete the
study; five of those who dropped out were from the intervention
group compared to one in the placebo group. Weschta 2004 also
reported a high and unbalanced dropout rate (38% from the anti-
fungal arm compared with 18% from the control arm); five partic-
ipants (13%) in the treatment arm dropped out due to “intolerance
of the study medication”. We felt Shin 2004 to be at unclear risk of
attrition bias as the information regarding those who were eligible
for the trial but did not participate, and whether there were any
participants that did not finish the trial, was not clearly presented.
We judged the remaining five studies to be at low risk of attrition
bias.
Selective reporting
We assessed three studies as at unclear risk of bias due to selective
reporting:
In Kennedy 2005, some of the outcomes mentioned in the meth-
ods section were described as “not statistically different” in the
paper but results were not reported.
Some of the outcomes in the methods section in Weschta 2004
were only reported vaguely in the results. For example, for en-
doscopic score the paper states, “The median endoscopy scores were
almost identical in the AMB and control groups (4 vs 4) and did
not change remarkably after treatment.” In addition, a difference in
adverse effects between the groups was reported but details of the
type of event and the number of patients was not provided.
A protocol was available for Hashemian 2016, where endoscopic
score is listed as an outcome (IRCT138811063186N1). This out-
come was not reported in the published paper. In addition, stan-
dard deviations were not given and results for adverse effects were
not well reported although they were provided following personal
communication.
We assessed the remaining five studies to be at a low risk of bias.
We identified no protocols through any sources for these studies
but all of the outcomes as presented in the methods sections were
reported in the results sections.
Other potential sources of bias
Unvalidated instruments
We assessed five studies as having an ’unclear’ risk of bias due to
the use of potentially unvalidated measurement instruments.
Kennedy 2005 refers to a ’modified’ version of the (validated)
Lund-Mackay scoring system but does not provide a reference to
the modifications and the impact on the validation.
The Hashemian 2016 study, conducted in Iran, used the validated
SNOT-20 instrument but no details were presented for any val-
idation with regards to language translation. Neither Corradini
2006 nor Shin 2004 reported any outcomes of interest and we
classified them as having ’unclear’ risk of bias.
Weschta 2004 used their own instrument called the “rhinosinusi-
tis quality of life score (RQL)”, which was modified from the mini
Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ)
developed for people with rhinoconjunctivitis due to allergy
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(Juniper 1991). The modifications reduced the total number of
questions by half without details or evidence of whether the mod-
ification validation affected the face validity or responsiveness of
the instrument to detect changes. Due to the lack of information
regarding the validity of the instrument for chronic rhinosinusitis
patients, we did not include data for this outcome in the results.
The remaining studies used validated instruments and we assessed
them to be at low risk of bias.
Other
Ponikau 2005 reported imbalances in age and duration of chronic
rhinosinusitis between the groups with the people allocated to the
antifungal treatment group being older and having had chronic
rhinosinusitis for a longer time. The paper does not indicate
whether there was a statistical difference between the groups and
so we rated the study as having an unclear risk of bias. In Weschta
2004, the paper identifies that “...dropouts were accounted for by re-
cruitment of additional patients.” It was unclear howmany patients
this was relevant for and whether the process was randomised and
allocation concealment protected.
We assessed the six remaining studies as at low risk of bias.
Funding and declarations of interest
Funding
Three studies reported funding sources. One study was funded by
a pharmaceutical company (Kennedy 2005). Two studies reported
funding from academic or governmental sources (Hashemian
2016; Ponikau 2005). The remaining five studies did not present
information on funding sources (Corradini 2006; Ebbens 2006;
Liang 2008; Shin 2004; Weschta 2004).
Declarations of interest
Ponikau 2005 declared that one of the funding organisations
owned a patent for which the first author was listed as the inven-
tor and that a license agreement had been signed with Accentia
Pharmaceutical Inc. The patent states: “the invention involves ad-
ministrating an antifungal agent such that it contact mucus [sic]in
an amount, at a frequency, and for a duration effective to prevent,
reduce, or eliminate non-invasive fungus-induced rhinosinusitis.”
In two studies, although declarations were not explicitly stated,
two had affiliations with pharmaceutical companies. Ebbens 2006
declared that three of the authors had consultancy arrangements
with pharmaceutical companies, and three authors had Novartis
as their affiliation in Kennedy 2005.
One study explicitly reported that the authors declared no conflicts
of interest (Hashemian 2016), and no information was presented
in four studies (Corradini 2006; Liang 2008; Shin 2004; Weschta
2004).
Effects of interventions
See: Summary of findings for the main comparison Topical
antifungal versus placebo/no treatment for chronic rhinosinusitis;
Summary of findings 2 Systemic antifungal versus placebo/no
treatment for chronic rhinosinusitis
Comparison 1: Topical antifungals versus placebo or
no treatment
Seven studies (437 participants) were included in this comparison
(Corradini 2006; Ebbens 2006; Hashemian 2016; Liang 2008;
Ponikau 2005; Shin 2004; Weschta 2004).
Primary outcomes
Disease-specific health-related quality of life
Although four studies reported disease-specific health-related qual-
ity of life using validated instruments, the data were difficult to
interpret for a number of reasons:
• A variety of different instruments were used and the length
of scales (e.g. RSOM-31) was not reported in some studies.
• Some studies suggested that the scoring system or scale had
been modified from the validated version but did not provide
full details. Weschta 2004 did not use a validated instrument,
which biases the results towards not detecting a difference due to
the loss of validity and ability to detect differences.
• There were a variety of ways in which the data were
reported in the studies, for example change from baseline versus
endpoints, means and standard deviations versus medians with
ranges.
• The data were likely to be not normally distributed in at
least three of the studies.
Considering of all of these factors we have summarised the results
narratively and presented them in full in Table 2.
All four of the studies reported no statistically significant difference
between groups.
• Ebbens 2006 (116 participants) reported the change from
baseline using the Rhinosinusitis Outcome Measure-31 (RSOM-
31; range: 0 to 775, lower = better quality of life) at 13 weeks as
means with standard deviations. Neither group had a large mean
change from baseline values (3.6 points and 17 points change on
a scale of 775 in the antifungal and placebo groups, respectively)
but there was no significant difference between the groups (P =
0.35).
• Hashemian 2016 (48 participants) reported the endpoint
values using the SNOT-20 quality of life instrument (range 0 to
100; lower = better quality of life) at eight weeks. The standard
deviations (provided from personal correspondence with the
authors) suggest that the data may be skewed based on their size
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compared to the mean. There was no difference between the
groups at the end of treatment (P = 0.76).
• Ponikau 2005 (24 participants) reported the change from
baseline using the SNOT-20 quality of life instrument at six
months. The results were presented as medians with ranges,
which may be because of the small sample size or because the
authors felt the data to be skewed. There was no statistically
significant difference in change from baseline values between the
groups (P = 0.72, Wilcoxon rank sum test).
• Liang 2008 (64 participants) reported the endpoint values
using the Chinese RSOM-31 values at four weeks. The results
were presented as medians with ranges and the data appeared to
be highly skewed. The median score was lower in the antifungal
group but the result was not significant (P = 0.091).
Disease severity (combined or individual symptom scores)
Two studies (176 participants), recruiting only patients with
chronic rhinosinusitis with nasal polyps, reported disease severity
as the sum of five individual symptom scores.
• Ebbens 2006 (116 participants) measured the symptoms of
nasal blockage, rhinorrhoea, facial pain, postnasal drip and
anosmia, each on a visual analogue scale (VAS) of 0 to 10 cm
(converted to 0 to 100). The paper presents the mean and
standard deviation for the mean change in total symptom score
(range: 0 to 500) after 13 weeks of treatment. Both antifungal
and placebo groups experienced small reductions in symptom
score with the following mean change from baseline (standard
deviation (SD)) values: placebo group: -21.1 (101.2); antifungal
group: -3.1 (82.8). The difference between the groups is not
significant (P = 0.31)
• Weschta 2004 (60 participants) measured the symptoms
nasal blockage, facial pain, smell disturbance, nasal discharge and
sneezing, each on a scale of 0 to 10. The paper presents the
median and interquartile ranges for the total symptom score
(range: 0 to 50) after eight weeks of treatment. There is no
indication that the results are significantly skewed. After
treatment, the median symptom score was lower (less severe
symptoms) in the control group (16.5; 12.0 to 24.0) compared
to the group allocated to antifungal treatment (26.0; 21.3 to
29.8). This result was statistically significant (P < 0.005).
Significant adverse effects: hepatic toxicity (systemic
antifungals)
This outcome was not relevant for the analysis of topical antifun-
gals.
Secondary outcomes
Generic health-related quality of life
Ebbens 2006 (116 participants) reported generic health-related
quality of life using the short form-36 (SF-36), although they
reported the physical and mental component scores separately (0
to 100, lower scores = better quality of life) and did not report an
overall score. The mean difference in mean change from baseline
values between the antifungal and placebo groups after 13weeks of
treatment was -0.80 for the physical component (95% confidence
interval (CI) -3.66 to 2.06) and -2.20 for the mental component
score (95% CI -5.46 to 1.06). It is uncertain whether there is a
difference between the groups (Analysis 1.1).
Other adverse effects: gastrointestinal disturbances, allergic
reactions (systemic antifungals)
This outcome is not relevant for topical antifungals.
Other adverse effects: epistaxis, headache, local discomfort
(e.g. itching, mild burning) (topical antifungals)
Epistaxis
Only Ebbens 2006 (116 participants) specifically reported epis-
taxis as an adverse effect, which was reported by two participants
in each group. Three other studies stated that no participants had
adverse effects (other than local discomfort) in either treatment
group (Corradini 2006; Ponikau 2005; Shin 2004); it is therefore
assumed that no participants had epistaxis (risk ratio (RR) 0.97,
95% CI 0.14 to 6.63; 4 studies; 225 participants) (Analysis 1.2).
Headache
Only Ebbens 2006 (116 participants) reported headache as an ad-
verse effect, although Ponikau 2005 specifically stated that they
would not be reporting headache as it was a symptom of chronic
rhinosinusitis as well as a possible adverse effect. Two studies stated
that no participants had adverse effects (other than local discom-
fort) in either treatment group (Corradini 2006; Shin 2004), so it
is assumed that no participants had headache (RR 1.26, 95% CI
0.60 to 2.63; 3 studies; 195 participants) (Analysis 1.3).
Local discomfort
Five studies reported data on local irritation that could be included
in a meta-analysis. Where irritation was observed in the antifun-
gal treatment arm it was described as a ’slight burning sensation’
(Hashemian 2016), ’nasal burning’ (Ponikau 2005), or ’skin itch-
ing’ (Liang 2008) (RR 2.29, 95% CI 0.61 to 8.62; 5 studies; 312
participants) (Analysis 1.4).
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Furthermore, two studies made statements about local irritation
but the numbers for each group were not available. Weschta 2004
identified significantly more participants in the amphotericin B
group who reported “nasal burning” (P < 0.005) and Shin 2004
indicated that some participants reported “mild nasal discomfort
due to a burning sensation” but did not report how many people
this affected or to which group they were allocated.
Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Kennedy)
Extent of polyps
Three studies presented data for the extent of nasal polyps after
treatment.
• Hashemian 2016 (54 participants) assessed polyp size in
each nostril using a range of 0 to 4 (0 = no polyp, 4 = polypoid
changes below the lower edge of the inferior turbinate; total
range: 0 to 8). No significant difference in final polyp score
between the groups was reported at eight weeks (P = 0.38).
• Ponikau 2005 (30 participants), using the same scale as
Hashemian 2016, reported the change in the extent of polyps
from baseline in each treatment group as medians and ranges.
They identified no significant difference between the treatment
arms at three months (P = 0.47) but a significantly larger
reduction in polyp size in the antifungals group compared to
placebo (P = 0.038) at six months.
• Weschta 2004 (78 participants) assessed polyp size in each
nasal cavity using a range of 0 to 3 (0 = no polyps; 3 = polyps fill
whole nasal cavity; total range: 0 to 6). The results are not well
reported but the authors state: “The median endoscopy scores were
almost identical in the AMB and control groups (4 vs 4) and did not
change remarkably after treatment.”
Endoscopy score
Two studies used an endoscopy score to compare the groups after
treatment.
• Ebbens 2006 assessed the amount of mucosal disease by
measuring nasal secretions, nasal polyps and nasal crusting each
on a scale of 0 to 2 (0 = absent, 2 = severe) in predefined areas
(e.g. middle meatus, ethmoid region). Sum scores were
calculated by adding all independent values for both nostrils but
the total possible range is not given in the paper. The data are
presented as mean change in endoscopy scores from baseline
values. The authors found no difference between the groups (P =
0.64) after 13 weeks treatment.
• Liang 2008 measured oedema, discharge, polyps, crusting
and scarring, all graded from 0 (normal) to 2 (severely diseased).
The total range is not provided but is likely to be 0 to 10. The
data are presented as the median endoscopy scores at the end of
treatment. The authors found no difference between the groups
(P = 0.944) after four weeks treatment.
Computerised tomography (CT) scan score (e.g. Lund-
Mackay)
Three studies reported CT scan scores, although different scales
were used:
• Hashemian 2016 (48 participants) measured mucosal
thickening, scored on scale of 0 to 3 (0 = no thickening) for each
of the frontal, maxillary, sphenoid and ethmoid sinuses, the nasal
passages and ostiomeatal complexes. Each of the scores was
summed to give a final range from 0 to 30 points (from personal
communication with authors). The study showed that there was
no difference in CT scores between the topical antifungal and
placebo groups (standardised mean difference (SMD) -0.22,
95% CI -0.79 to 0.34) (Analysis 1.5).
• Weschta 2004 (60 participants) used the Lund-Kennedy
score, which measures opacification on a scale of 0 to 4 (0 = not
opacified) for each of the of the maxillary, anterior and posterior
ethmoidal, sphenoidal and frontal sinuses. Each of the scores was
summed to give a final range from 0 to 40 points. After
treatment, the median CT scan scores in the antifungal
treatment group were 26.5 (interquartile range (IQR) 19.5 to
35.8) and in the control group were 26.5 (IQR 23.0 to 32.0).
This result was not statistically significant (P > 0.2).
• Ponikau 2005 used digitised coronal CT scans to measure
the percentage of airspace occluded by inflammatory mucosal
thickening. There was a significant decrease in the mean
percentage of air space occluded between the group receiving
topical antifungals (-8.8%, standard deviation (SD) 13.6) and
the placebo group (2.5%, SD 10.3).
Subgroup analyses
We had planned to present subgroup analyses by presence of aller-
gic fungal rhinosinusitis and eosinophilic status. However, these
factors were not well presented in the studies and so subgroup
analysis was not possible. The presence of nasal polyps was re-
ported but as only Liang 2008 exclusively included recruited pa-
tients without nasal polyps and meta-analysis was not possible for
the primary outcome, we did not complete subgroup analyses. We
planned to investigate the other factors identified in the methods
(patient age, dose, duration of treatment, method of delivery, class
of antifungal agent) in the event of statistical heterogeneity, but
this situation did not occur.
Comparison 2: Systemic antifungals versus placebo or
no treatment
One study was included in this comparison (Kennedy 2005; 53
participants), which compared terbinafine tablets with placebo
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tablets in patients with chronic rhinosinusitis (unknown polyps
status) for six weeks.
Primary outcomes
Disease-specific health-related quality of life
Kennedy 2005 (53 participants) measured disease-specific health-
related quality of life using the Rhinosinusitis Disability Index
(RSDI). Values for the RSDI results were not given but the authors
state ”no differences were observed“ at any time point measured.
Disease severity (combined or individual symptom scores)
Kennedy 2005 (53 participants) measured the symptoms of facial
pain/pressure, facial congestion and nasal discharge. No values
were reported but the authors state that no differences between
the groups were observed.
Significant adverse effects: hepatic toxicity (systemic
antifungals)
Although one patient in the terbinafine group had increased as-
partate aminotransferase (AST), alanine aminotransferase (ALT)
or gamma-glutamyl (GGT) levels, the paper goes on to state that
”No clinically significant difference between treatment groups was ob-
served in liver function tests (LFT) at week 3 or week 6“ (RR 3.35,
95% CI 0.14 to 78.60; 53 participants) (Analysis 2.1).
Secondary outcomes
Generic health-related quality of life
This outcome was not reported in the included study.
Other adverse effects: gastrointestinal disturbances, allergic
reactions (systemic antifungals)
Kennedy 2005 (53 participants) reported that one person experi-
enced gastrointestinal disorders in the terbinafine group compared
with three people in the placebo group (RR 0.37, 95% CI 0.04 to
3.36) (Analysis 2.2).
Other adverse effects: epistaxis, headache, local discomfort
(e.g. itching, mild burning) (topical antifungals)
This outcome is not relevant for systemic antifungals.
Endoscopic score (depending on population, either nasal
polyps size score or endoscopy score, e.g. Lund-Kennedy)
This outcome was not reported in the included study.
Computerised tomography (CT) scan score (e.g. Lund-
Mackay)
Kennedy 2005 reported the CT scan score in two ways: the
percentage change from baseline in the total opacification score
(higher = worse) (mean difference (MD) -0.14, 95% CI -19.22 to
18.94; 49 participants) (Analysis 2.3) and the percentage change
frombaseline total in obstruction score of the frontal recess,middle
meatus infundibulum and sphenoethmoid recess (higher = worse)
(MD -4.40, 95% CI -40.12 to 31.32; 47 participants) (Analysis
2.4). No statistical difference was observed in either group and
large standard deviations indicate very large variations in the re-
sults.
Subgroup analyses
As only one study was included in this comparison, subgroup
analyses were not possible.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Systemic antifungal versus placebo/no treatment for chronic rhinosinusitis
Patient or population: chronic rhinosinusit is
Intervention: systemic ant if ungal
Comparison: placebo/ no treatment
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evi-
dence
(GRADE)
What happens
Without systemic anti-
fungal
With systemic antifun-
gal
Difference
Heath-related quality of
lif e (HRQL)
Assessed with: Rhinos-
inusit is Disability Index
(RSDI)
Follow-up: 6 weeks
of part icipants: 53
(1 RCT)
Values for the RSDI results were not provided in the paper but the authors state that “no differences
were observed” at any t ime point measured
⊕⊕©©
LOW 1
Systemic ant if ungals
may lead to lit t le or no
dif ference in disease-
specif ic health-related
quality of lif e, com-
pared with placebo, for
pat ients with chronic
rhinosinusit is
Disease severity score
Assessed with: overall
evaluat ion of sinusit is
measured on a 4-point
scale
Follow-up: 6 weeks
of part icipants: 53
(1 RCT)
Symptoms of facial pain/ pressure, facial congest ion and nasal discharge were measured. No
values were reported but the authors state that ”no differences were observed [between the treatment
groups]“.
⊕⊕©©
LOW 1
Systemic ant if ungals
may lead to lit t le or
no dif ference in disease
severity score, com-
pared with placebo, for
pat ients with chronic
rhinosinusit is
Adverse ef fects - hep-
at ic toxicity
Follow-up: 6 weeks
of part icipants: 53
(1 RCT)
RR 3.35 (95%CI 0.14 to
78.60)
Study populat ion ⊕⊕©©
LOW 2
Systemic ant i-
fungal agents may lead
to more hepat ic toxi-
city events compared
with placebo for pa-
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t ients with chronic rhi-
nosinusit is
No events were re-
ported
- -
Adverse ef fects -
gastrointest inal distur-
bances
Follow-up: 6 weeks
of part icipants: 53
(1 RCT)
RR 0.37 (95%CI 0.04 to
3.36)
Study populat ion ⊕⊕©©
LOW3
Systemic ant i-
fungal agents may lead
to more gastrointest i-
nal disturbances com-
pared with placebo for
pat ients with chronic
rhinosinusit is
10.7% 4.0%
(0.4 to 36.0)
6.7% fewer
(10.3 fewer to 25.3
more)
Adverse ef fects - aller-
gic react ions
No study reported this outcome
Generic health-related
quality of lif e
No study reported this outcome
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RR: risk rat io; RSDI: Rhinosinusit is Disability Index
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by one level due to imprecision: results come f rom one small study (44 part icipants). Downgraded by one level
due to risk of bias: the paper does not present quant itat ive results and so is at risk of select ive outcome report ing.
2Downgraded by two levels due to imprecision: results come f rom one small study (44 part icipants) report ing one event in the
systemic ant if ungal group, leading to very wide conf idence intervals.
3Downgraded by two levels due to imprecision: results come f rom one small study (44 part icipants) report ing three events in
the placebo group and one event in the systemic ant if ungal group, leading to wide conf idence intervals.27
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D I S C U S S I O N
Summary of main results
Topical antifungals versus placebo
Seven studies (437 participants) comparing antifungals with
placebo or no treatment were included. There were a variety of dif-
ferent administration methods used from low-volume nasal sprays
to high-volume nasal irrigation. The inclusion criteria of the stud-
ies ranged from excluding patients with nasal polyps (one study)
to including only patients with nasal polyps (three studies). It was
difficult to analyse the data as the outcomes were measured using
different instruments (some with potential validation issues) and
the results were reported in different ways (means and medians).
The efficacy outcomes of both disease-specific and generic
health-related quality of life and disease severity as measured
by patient-reported symptoms did not appear to differ between
the topical antifungals and placebo/no treatment groups. With re-
gards to adverse effects there may have been more local irritation
events in the group receiving antifungal agents compared with
placebo. It is uncertain if there was a difference between the groups
with regards to developing headaches or epistaxis. No differences
were found between the groups in CT scan scores or endoscopy
scores.
There was considerable variation in the doses of antifungals used in
the studies. The dose of amphotericin B used ranged from 0.8 mg/
day to 20 mg/day with varying concentrations, dosing regimens
and delivery methods. The dose of fluconazole used was 1.2 mg
per day. In many cases the dose was considered to be low.
Systemic antifungals versus placebo
One study (53 participants) compared systemic antifungals
(terbinafine tables) against placebo. No statistically significant
difference between the groups was observed in disease-specific
health-related quality of life, disease severity as measured by
patient-reported symptoms or CT scan scores. One patient in the
systemic antifungals group had elevated liver function tests but
fewer people reported gastrointestinal disturbances in the systemic
antifungal group compared to the placebo group, although the re-
sults were not significantly different between the groups in either
case. The dose of terbinafine used in the study was over twice the
recommended daily dose in the British National Formulary (BNF
2018), with the rationale being that the dosing was as used for in-
vasive fungal sinusitis. This study may have been limited by use of
the CT scan scores as the primary outcome measure; radiological
changes correlate poorly with symptom scores.
Overall completeness and applicability of
evidence
The evidence included a wide range of participants with chronic
rhinosinusitis including those with and without nasal polyps. The
included populations were representative of the average chronic
rhinosinusitis population. However, the presence of allergic fungal
rhinosinusitis, eosinophilic fungal rhinosinusitis or eosinophilic
mucinous rhinosinusitis was not well reported within the papers
and in fact these patients were excluded in some of the studies.
Six of the seven studies that reported the age of the participants
only included adults in their trial populations. The seventh study
extended their inclusion criteria to include children from the age of
12 years. No evidence exists for children below 12 years, although
chronic rhinosinusitis is predominantly a disease of adulthood.
Quality of the evidence
We assessed the evidence included within this review to be of
low or very low quality. Although, for the most part, we did not
consider the risk of bias in the studies to be very high and they
were generally well conducted, the studies were typically very small
(30 to 116 participants) with only one study having more than 80
participants. The results of the studies were often poorly reported
using a range of different instruments and methods tomeasure the
same outcome. Inparticular, the validity of the instruments used to
measure quality of life and symptom scores was of concern. Some
studies appeared to have modified validated instruments meant
for other populations without referencing the further validation,
with potential adverse consequences for the validity and reliability
of the results. Even when a validated instrument was cited, it was
unclear if a validated instrument for the particular language and
setting had been applied (Wild 2005).
Potential biases in the review process
Due to the differences in the instruments used for measuring the
primary efficacy outcome (disease-specific health-related quality of
life) and the ways in which this outcome had been reported (means
with standard deviations versusmedianswith ranges), wemade the
decision not to try to meta-analyse the results. We had concerns
that some of the data were from skewed distributions and felt
that completing a meta-analysis may lead to spurious conclusions.
Therewas some thought that theremay be ’sub’ populationswithin
the overall trial population who might respond differently to the
antifungal treatment but not enough information was available to
be able to investigate this.
The definition of the population inclusion criteria excluded pa-
tients who had recently undergone surgery. However, it is noted
that allergic fungal rhinosinusitis is often identified during or even
after surgery and so by excluding the post-surgical population we
may have missed some of these studies.
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Agreements and disagreements with other
studies or reviews
One recent paper, published after the final date of the literature
search, compared amphotericin B with placebo in 80 patients with
chronic rhinosinusitis (20% of whom had nasal polyps) (Yousefi
2017). Their results are consistent with the findings of this re-
view in that their study found no statistically significant differ-
ence between the groups at three months for any of the outcomes:
patient-reported symptom severity (nasal obstruction, post-nasal
drip, sense of smell and facial pain), health-related quality of life or
CT scores. The lack of any differencemost probably represents the
fact that 80% of participants had chronic rhinosinusitis without
nasal polyps, where fungal aetiology is unlikely to play a role.
The results of the previous Cochrane Review and another more
recent systematic review reach the same conclusions as this review
(Mistry 2014; Sacks 2011). Both agree that there is no convincing
evidence to support the use of antifungals in chronic rhinosinusi-
tis. The authors of previous reviews share our concern regarding
the clinical diversity of the included populations within the trials,
particularly with regard to diagnosis, with acknowledgement that
the population often includes patients with both chronic rhinosi-
nusitis and allergic fungal rhinosinusitis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to the very low quality of the evidence, it is uncertain whether
or not the use of topical or systemic antifungals has an impact
on patient outcomes in adults with chronic rhinosinusitis com-
pared with placebo or no treatment. There is no evidence avail-
able to assess the efficacy of antifungal agents for specific sub-
groups of chronic rhinosinusitis, such as allergic fungal rhinos-
inusitis, eosinophilic fungal rhinosinusitis or eosinophilic muci-
nous rhinosinusitis, but this finding is very much limited by the
study designs, which did not focus specifically on these specific
fungal subgroups and also had marked variation in the treatment
regimens.
The evidence in this review is for patients who did not undergo
surgery.
Implications for research
As of November 2017, we have found eight studies of topical or
systemic antifungal agents for patients with chronic rhinosinusitis
who did not have surgery. There is low-quality evidence (i.e. we
are uncertain about the estimates) that there is little or no differ-
ence between antifungals (topical or systemic) and placebo or no
treatment, in terms of quality of life or patient-reported symptom
scores. The quality of the evidence for adverse effects is low or very
low due to inadequate reporting methods and small study sizes.
We considered the potential for future research into the use of
antifungal agents and feel that this area of research might not be
prioritised above research for other standard interventions as iden-
tified by the other reviews in this suite (Chong 2016a; Chong
2016b; Chong 2016c; Head 2016a; Head 2016b; Head 2016c). If
research is carried out, open questions remain about the use of top-
ical and systemic antifungals in patients with specific subtypes of
chronic rhinosinusitis: allergic fungal rhinosinusitis, eosinophilic
fungal rhinosinusitis or eosinophilic mucinous rhinosinusitis.
This review is one of a suite of reviews on medical treatments for
chronic rhinosinusitis, each of which features its own research rec-
ommendations. Across all reviews, key features of future research
are as follows:
• Trials should be adequately powered and imbalances in
prognostic factors (for example, prior sinus surgery) must be
accounted for in the statistical analysis.
• Study participants should be diagnosed with chronic
rhinosinusitis using the EPOS 2012 criteria and should
primarily be recruited based on their symptoms. Different
patient phenotypes (that is, those with and without nasal polyps)
should be recognised and trials should use stratified
randomisation within these subgroups or focus on one or other
of the phenotypes. In addition, subcategories of chronic
rhinosinusitis such as allergic fungal rhinosinusitis, eosinophilic
fungal rhinosinusitis and eosinophilic mucinous rhinosinusitis
should be well defined and diagnosed at the start of the trial with
stratification at randomisation. Ideally multi-centre studies
focused on these fungal subgroups would be more useful in
addressing the role of both topical and systemic antifungals; some
of the excluded case series suggest that an effect may be present.
• Studies should focus on outcomes that are important to
patients and use validated instruments to measure these.
Validated chronic rhinosinusitis-specific health-related quality of
life questionnaires exist, for example the Sino-Nasal Outcome
Test-22 (SNOT-22). Patients may find dichotomised outcomes
easiest to interpret; for example the percentage of patients
achieving a minimal clinically important difference (MCID) or
improvement for that outcome. Such MCIDs or cut-off points
should be included in the study protocol and clearly outlined in
the methods section.
• Trials and other high-quality studies should use consistent
outcomes and adhere to reporting guidelines, such as
CONSORT, so that results can be compared across future trials.
There is now a core outcome set for chronic rhinosinusitis trials
that should guide research teams in setting these trials henceforth
(CHROME 2017).
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Corradini 2006
Methods 4-arm, non-blinded, parallel-group RCT, with unclear duration of treatment and 20
months duration of follow-up
Participants Location: Italy, 1 site
Setting of recruitment and treatment: university hospital
Sample size: 48
• Number randomised: 23 in antifungal group, 25 in no antifungal group
• Number completed: as per number randomised
Participant (baseline) characteristics:
• Age: not reported
• Gender: not reported
• Main diagnosis: nasal polyposis with evidence of fungal infection
• Presence of allergic fungal rhinosinusitis: 0% with AFRS
• Presence of eosinophilic CRS: not reported
• Polyps status: 100% with polyps
• Previous sinus surgery status: not reported
• Other important effect modifiers, if applicable:
◦ Aspirin sensitivity: 15 (77%) of 89 randomised
◦ Complete aspirin triad syndrome: 18 (20%) of 89 randomised
Inclusion criteria: nasal polyposis with fungal infection. Confirmed via medical history
and physical examination, skin prick tests, measurement of specific IgE and nasal lavage
Exclusion criteria: patients with nasal polyps but without evidence of fungal infection
Interventions Intervention (n = 23): amphotericin B (50 mg × 15 mL of 5% glucose solution),
inhalation
• 0.24 mL/day (equal to 0.8 mg of amphotericin B) 6 times/week for 1 month,
followed by
• 0.16 mL/day (equal to 0.5 mg of amphotericin B) 6 times/week as the
maintenance dose (treatment duration is not well defined)
Comparator group (n = 25): no antifungal treatment
Use of additional interventions (common to both treatment arms):
Medical polypectomy: 40 mg of triamcinolone retard intramuscularly 3 times every 10
days (total dose 120 mg)
Lysine acetylsalicylate (LAS): after a nasal provocation test with LAS patients were treated
with LAS inhalation (4mg/day; 6 times/week) (treatment duration at this dose is assumed
to be 19 months)
Outcomes Outcomes of interest in the review:
Primary outcomes: none reported
Secondary outcomes: none reported
Other outcomes reported by the study:
Polyp recurrence at 20 months, sensitisation to allergens
Funding sources No information provided
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Corradini 2006 (Continued)
Declarations of interest No information provided
Notes Adverse effects were not reported as an outcome but there is one statement reading “LAS
and amphotericin B treatment was well tolerated by all patients and no adverse reactions
were observed.”
This paper presents a 4-arm study
Group A: surgical endoscopic transnasal ethmoidectomy then topical endonasal treat-
ment with LAS - this group is not included as all participants underwent surgery
Group B: medical polypectomy with triamcinolone retard IM, then topical endonasal
treatment with LAS (included in this review)
Group C: surgical endoscopic transnasal ethmoidectomy then topical endonasal treat-
ment with LAS and amphotericin B - this group is not included as all patients underwent
surgery
Group D: medical polypectomy with triamcinolone retard IM, then topical endonasal
treatment with LAS and amphotericin B (included in this review)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”were randomly assigned“
Comment: no information about methods
used
Allocation concealment (selection bias) Unclear risk Comment: no information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: 4 different treatment arms with
different treatment regimens. Blinding is
not likely to have been completed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: blinding of outcome assess-
ment was reported but it was assumed that
it was not completed as there is no men-
tion of blinding nor placebo control in the
paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: it appears that all of the peo-
ple who were randomised were included in
the results. No discussion of withdrawals,
which is surprising in a 20-month study
Selective reporting (reporting bias) Low risk Comment: no published protocol on Clin-
icalTrials.gov or EuropeanTrialsRegister. It
appears that all of the outcomes presented
in the methods are reported in the results
section
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Corradini 2006 (Continued)
Other bias (non-validated instrument) Unclear risk Comment: no outcomes of interest for this
review. Standard endoscopy and imaging
instruments presumed to have been used,
but no further information
Other bias Low risk Comment: no other bias identified
Ebbens 2006
Methods 2-arm, double-blind, multi-centre, parallel-group RCT, with 13-week duration of treat-
ment and follow-up
Participants Location: 4 countries (Belgium, the Netherlands, Spain, UK); 6 sites
Setting of recruitment and treatment: 6 tertiary care otorhinolaryngology clinics
Sample size: 116
• Number randomised: 59 in intervention, 57 in comparison
• Number completed: 51 in intervention, 48 in comparison
Participant (baseline) characteristics:
• Mean age (SD): group 1: 48.1 (11.1); group 2: 45.4 (12.7)
• Gender M/F: 39 (33.6%)/77 (66.4%)
• Main diagnosis: adult patients with CRS with or without nasal polyps
• Presence of allergic fungal rhinosinusitis: 0% - patients with allergic fungal
sinusitis were not eligible to enrol
◦ allergy to fungi: group 1: 14 (24%); group: 2 9 (16%)
• Presence of eosinophilic CRS: not reported
• Polyps status: group 1: 47 (80%); group 2: 48 (84%)
• Previous sinus surgery status: 100% (entry criteria)
◦ Mean number of surgical interventions (SD): group 1: 3.3 (3.0); group 2: 3.
2 (2.5)
• Other important effect modifiers:
◦ Asthma: group 1: 32 (54%); group 2: 30 (53%)
◦ Acetylsalicylic acid intolerance: group 1: 17 (29%); group 2: 10 (18%)
◦ Allergy (general): group 1: 29 (49%); group 2: 37 (65%)
• Use of local steroids: group 1: 41 (70%); group 2: 38 (67%)
Inclusion criteria: patients older than 18 years and 1)clinical signs and symptoms related
to CRS and/or NP (nasal congestion, nasal discharge, headache and/or facial pain) that
are present persistently or recurrently (i.e. intermittent or present > 6 weeks after the last
surgical procedure) for a total period of at least 6 months; 2) endoscopic signs of CRS
and/or NP; 3) previous history of ESS sinus CT scan score of 5 according to the Lund-
Mackay scoring system performed within a period of 2 months before randomisation
Exclusion criteria: patients with allergic fungal sinusitis were not eligible to enrol
Other reasons for exclusion were: 1) nasal infections that can be explained by anatomical
defects, immunoglobulin deficiency, complement deficiency, cystic fibrosis, Wegener,
sarcoidosis, vasculitis or chronic granulomatous disease; 2) AIDS or known to be HIV-
positive; 3) positive culture forMycobacterium spp; 4) osteoporosis; 5) chronic renal and/
or hepatic failure; 6) female patients who are pregnant or lactating; 7) inadequate use of
contraceptive precautions; 8) administration of homeopathic preparations to the nose
or paranasal sinuses; 9) chronic use of systemic steroids; 10) use of nasal decongestants
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Ebbens 2006 (Continued)
or local antibiotics; 11) oral antifungal therapy; 12) immunosuppressive therapy; 13)
previous randomisation into the study; 14) enrollment in other investigational drug
trials; 15) psychiatric, addictive or any other disorder compromising the ability truly to
give informed consent; 16) concerns for compliance with the protocol procedures
Interventions Intervention (n = 59): amphotericin B; in sterile water containing 2.5% glucose, re-
sulting in a clear yellow solution. 25 mL solution (100 µg/mL) applied to each nostril
twice daily using an Emcur (Rhinicur) nasal douching device. Total daily dose = 10 mg
amphotericin. Treatment duration = 13 weeks
Comparator group (n = 57): placebo nasal lavage (dissolving 3.4 mL/L Cernevit in
sterile water containing 2.5% glucose), resulting in a clear yellow solution. Cernevit, a
multivitamin preparation for use intravenously, was chosen as placebo for its colour and
absence of toxic effects on nasal mucosa. Treatment duration = 13 weeks
Use of additional interventions (common to both treatment arms):
Intranasal corticosteroids: allowed when used consistently during the whole trial period
(group 1: 41 (70%); group 2: 38 (67%))
Antibiotics: were allowed at clinical exacerbation (either amoxicillin/clavulanic acid 500/
125 mg 3 times daily or ciprofloxacin 750 mg twice daily combined with clindamycin
600 mg 3 times daily), but only after aerobic and anaerobic cultures were performed by
suction and injection in a port-a-cul (group 1: 12 (20%); group 2: 10 (18%))
Systemic steroids: were allowed for a maximum period of 14 days when prescribed for a
disease other than upper airway pathology (group 1: 1 (2%); group 2: 0 (0%))
(Combined antibiotic and systemic treatment required in group 1: 3 (5%); group 2: 2
(4%))
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific: Rhinosinusitis Outcome Measure-
31 (RSOM-31) measured at baseline and 13 weeks after start of the trial. Lower
RSOM-31 score implies less impact on quality of life. (Range not given in the paper
but standard RSOM-31 range is 0 to 755).
• Disease severity symptom score: total VAS score (0 to 10 cm), which is the sum of
individual VAS scores for: nasal blockage, rhinorrhoea, facial pain, postnasal drip and
anosmia) at baseline, 2 and 6 weeks after start of the trial. Lower VAS = less severe
symptoms.
• Significant adverse effect (systemic antifungals): hepatic toxicity
Secondary outcomes:
• Health-related quality of life, generic: Short Form-36 (SF-36), separated into the
physical and mental scores. Lower SF-36 values = better quality of life.
• Endoscopy:
◦ ”Amount of mucosal disease“: the presence or absence of nasal secretions (0
= absent, 1 = clear to opaque, 2 = purulent), amount of crusting (0 = absent, 1 = mild,
2 = severe) and presence or absence of nasal polyps (0 = absent, 2 = present) in
predefined areas (e.g. middle meatus, ethmoid region). Sum scores were calculated by
adding all independent values for both nostrils. The proportion of the total nasal cavity
volume occupied by polyps was estimated (as per method by Johansson) at 2, 6 and 13
weeks after start of the trial
◦ Change in polyps score
• Adverse effects (topical antifungals): epistaxis (measured on a 0 to 10 VAS),
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Ebbens 2006 (Continued)
headache (measured on a 0 to 10 VAS), local discomfort (itching of nose, itching of
throat and itching of ears were measured on 0 to 10 cm VAS). Lower = less severe
symptoms. Measured at baseline, 2 and 6 weeks after start of the trial.
• Adverse effects (systemic antifungals): gastrointestinal disturbances, allergic
reactions
Other outcomes reported by the study:
• Change in nasal patency (peak nasal inspiratory flow)
• Levels of pro-inflammatory cytokines, chemokines and growth factors and
albumin
Funding sources No information provided
Declarations of interest • GK Scadding has consultant arrangements with GlaxoSmithKline, Schering-
Plough and RhinoPharma and is on the speakers’ bureau for GlaxoSmithKline, Merck
Sharp & Dohme and Schering-Plough
• V Lund has consultant arrangements with Schering- Plough
• WJ Fokkens has consultant arrangements with GlaxoSmithKline and Schering-
Plough
The rest of the authors declared that they have no conflict of interest
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Patients were randomly allo-
cated…using a computer-generated random-
ization schedule (block length of 4) provided
by theDepartment of Biostatistics, ... Separate
randomization lists were generated for each
participating center and given to each phar-
macy department. Patient numbers were se-
quentially assigned in time for each partici-
pating center.“
Comment: well-described randomisation
process
Allocation concealment (selection bias) Low risk Quote: ”Separate randomization lists were
generated for each participating center and
given to each pharmacy department.“
”Numbered light-rejecting bottles containing
either amphotericin B or placebo were pre-
pared and dispensed by an independent phar-
macist in each participating center to each pa-
tient on randomization.“
Comment: well-described process for con-
cealing allocation
40Topical and systemic antifungal therapy for chronic rhinosinusitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ebbens 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”No difference in appearance, taste,
or smell between placebo and amphotericin B
solutions could be detected.“
Comment: independent randomisation
and allocation. Efforts made to make treat-
ments as similar as possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”Randomization codes were revealed
to the researchers only when recruitment and
data collection were complete.“
Comment: all outcome assessment was
completed blind to the allocation of treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 8/59 (13.6%) and 9/57 (15.
8%) of participants dropped out in the am-
photericin B and placebo groups, respec-
tively. Reasons for dropout were similar be-
tween the 2 groups
Selective reporting (reporting bias) Low risk Comment: no protocol was identified on
theUSorEuropeanClinical TrialsRegistry.
All outcomes as reported in the methods
section are reported (as baseline values and
change from baseline) in the results section
Other bias (non-validated instrument) Low risk Comment: authors used RSOM-31, SF-36
and visual analogue scales, which are vali-
dated instruments
Other bias Low risk Comment: no additional sources of bias
were identified
Hashemian 2016
Methods 2-arm, double-blind, single-centre, parallel-group RCT, with 8 weeks duration of treat-
ment and follow-up
Participants Location: Iran, 1 site
Setting of recruitment and treatment: secondary care, hospital ENT clinic
Sample size: 54
• Number randomised: 27 in intervention, 27 in comparison
• Number completed: 24 in intervention, 24 in comparison
Participant (baseline) characteristics:
• Mean age (± SD): group 1: 38.25 (± 1.70); group 2: 39.75 (± 3.195)
• Gender (M/F): 34 (70.8%)/14 (29.2%)
• Main diagnosis: chronic rhinosinusitis (CRS)
• Presence of allergic fungal rhinosinusitis: not reported
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• Presence of eosinophilic CRS: not reported
• Polyps status (% with polyps): 21 (43.8%)
• Previous sinus surgery status: not reported
• Other important effect modifiers, if applicable: smoking status - smoker: 5 (10.
4%)
Inclusion criteria: adults (age >18 years)withCRSdiagnosed according to theAmerican
Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) criteria, which had
not been responsive to routine medical treatments
Exclusion criteria: patients who were pregnant, lactating or suffered from amajor illness
(such as cardiovascular disease, acute renal or liver disease, cancer or active malignancy).
Known sensitivity to fluconazole immune compromised patients patients with acute
complication of CRS superimposition of ARS (fever, acute pain, pressure on face)
antibiotic use in recent 7 days; systemic antifungal use in recent 7 days and systemic
steroid use in recent 30 days
Interventions Intervention (n = 27): fluconazole nasal drops 0.2% (12 drops per day, 2 times a day).
Total daily dose = 1.2 mg fluconazole. Treatment duration = 8 weeks
Comparator group (n = 27): placebo nasal drops (12 drops per day, 2 times a day).
Treatment duration = 8 weeks
Use of additional interventions (common to both treatment arms):
Fluticasone nasal spray 50 µg (2 puffs per day, 2 times a day)
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific, SNOT-20 range: 0 to 100, lower =
better quality of life, 8 weeks
Secondary outcomes:
• Endoscopy (polyps size or overall score) (Personal communication: No evidence of
disease (stage 0); Inflammatory mucosal changes confined to the middle meatus
superior to the lower edge of the middle turbinate (stage 1); Polypoid changes
between the lower edge of the middle turbinate and the root of the inferior
turbinate (stage 2); Polypoid changes between the root of the inferior turbinate
and the lower edge of the inferior turbinate (stage 3); Polypoid changes below the
lower edge of the inferior turbinate (stage 4). The stages of the 2 sides were added
(range, 0-8).)
• CT scan (Personal communication; range 0 to 30 points: mucosal thickening scored
on 0 to 3 range for each of frontal (2), maxillary (2), sphenoid (1) and ethmoid (2) sinuses,
nasal passages and OMC (2))
• Adverse effects (topical antifungals): local discomfort
Other outcomes reported by the study:
• None
Funding sources ”Academic research fund was provided by Hamadan University of Medical Sciences“
Declarations of interest ”The authors declare no conflicts of interest at all.“
Notes Registered in Iranian Registry of Clinical Trials: IRCT138811063186N1
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomization was done by tossing
a coin by an independent third party (ward
secretary).“
Comment: adequate randomisation
Allocation concealment (selection bias) Low risk Quote: ”… the bottles were coded by a third
party whowrote down the codes in a table and
the third party himself decoded the bottles at
the end of the study.“
Comment: randomisation completed by a
3rd party and clinicians were handed coded
bottles
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”…drug and placebo were exactly
identical in terms of their appearance and
could not be identified neither by the clini-
cian nor the patient.“
Comment: adequate details in paper to
demonstrate that sufficient efforts were
made to prevent the participants knowing
their allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”…drug and placebo were exactly
identical in terms of their appearance and
could not be identified neither by the clini-
cian nor the patient.“
Comment: adequate details in paper to
demonstrate that sufficient efforts were
made to prevent the participants knowing
their allocation for the outcome of SNOT-
20. For CT scan and endoscopic score it
is assumed that these were completed by
blinded clinician
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: 6/54 (11%) of randomised par-
ticipants did not complete the study. There
was no difference in the number of people
dropping out between the groups. The rea-
sons for dropping out were ”exacerbation
of disease“ (1 person) and voluntary refusal
to continue study (5 people)
Selective reporting (reporting bias) Unclear risk Comment: although the protocol is
available (IRCT138811063186N1), endo-
scopic score is not listed as an outcome.
Furthermore, the method for reporting en-
doscopic score and CT scan score are not
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reported in the published paper
Standard deviations for the data are not
given in the paper.
The results for adverse effects are not well
described.
Other bias (non-validated instrument) Unclear risk Comment: although SNOT-20 is a vali-
dated tool in CRS, it is unclear whether an
Iranian version was used. No information
on validity of the version was used with
regards to translation and cultural adapta-
tion. No details were given regarding the
criteria used for endoscopic score and CT
scan score and so it is not possible to say
whether these were validated instruments
Other bias Low risk Comment: no other bias identified
Kennedy 2005
Methods 2-arm, double-blinded, multicentre, parallel-group RCT, with 6-week duration of treat-
ment and 9-week duration of follow-up
Participants Location: United States; unclear number of sites
Setting of recruitment and treatment: not reported
Sample size: 53
• Number randomised: 25 in intervention, 28 in comparison
• Number completed: 21 in intervention, 23 in comparison
Participant (baseline) characteristics:
• Age mean (SD): terbinafine 49 (10); placebo 52 (13)
• Gender M(%)/F(%): 27(50.9%)/26 (49.1)
• Main diagnosis: CRS
• Presence of allergic fungal rhinosinusitis: not reported
• Positive fungal culture: terbinafine 17/25; placebo 24/28
• Presence of eosinophilic CRS: not reported
• Polyps status: not reported
• Previous sinus surgery status: not reported
• Other important effect modifiers, if applicable (e.g. aspirin sensitivity,
comorbidities of asthma): none reported
Inclusion criteria: all patients were required to have signs and symptoms of CRS for
a period of greater than 3 months before screening and to have failed previous medical
therapy
Diagnosis of CRS was based on AAO-HNS definitions. Patients were required to have
CT scan evidence of sinusitis (more than 25% opacification/mucoperiosteal thickening
in at least 2 of the major paranasal sinuses)
Exclusion criteria: sinus surgery within the 3 months before screening
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Interventions Intervention (n = 25): terbinafine, tablets, 625 mg/day, 6 weeks
Comparator group (n = 28): identical looking placebo tablets, 6 weeks
Use of additional interventions (common to both treatment arms):
Use of systemic antibiotics, oral and nasal steroids, anti-leukotriene inhibitors or antihis-
tamines was allowed during the trial, but the regimen was kept consistent from 6 weeks
before randomisation through to the end of the study
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, using disease-specific health-related quality of life
scores: Rhino-sinusitis Disability Index (RSDI): measured at 9 weeks
• Disease severity symptom score: patient’s overall evaluation of sinusitis (4-point
scale), measured at 9 weeks, unclear if higher or lower indicates worse symptoms
• Significant adverse effect (systemic antifungals): hepatic toxicity (as measured by
number of patients with increased AST, ALT or GGT - no definition of ”increased“
given)
Secondary outcomes:
• CT scan: (1) percentage change from baseline in CT opacification score. CT
scans were graded for extent of opacification at baseline and end of week 6 using a
modification (total opacification= 50) of the Lund-Mackay scoring system. (2) Total
right and left obstruction score of the frontal recess, middle meatus infundibulum and
sphenoethmoid recess
• Adverse effects (topical antifungals): epistaxis, headache, local discomfort
• Adverse effects (systemic antifungals): gastrointestinal disturbances, allergic
reactions
Other outcomes reported by the study:
• Patient’s and physician’s overall evaluation of sinusitis (4-point scale)
• Patient’s and physician’s evaluation of therapeutic response
• Percentage change from baseline in volume of inflammatory sinus mucosal disease
• Histologic examination
Funding sources Novartis pharmaceutical corporation
Declarations of interest No information provided. Authors acknowledge Novartis employee for preparation of
the manuscript. Three authors have Novartis as their affiliation
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomization was performed us-
ing a validated system that automated the
random assignment of treatment codes.“
Comment: automatic randomisation
45Topical and systemic antifungal therapy for chronic rhinosinusitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kennedy 2005 (Continued)
Allocation concealment (selection bias) Low risk Comment: as randomisation was auto-
mated it is assumed that the allocation to
treatment group was adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”Both the patient and investigator
were blinded to the treatment assignment.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”Both the patient and investigator
were blinded to the treatment assignment.“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”All randomized patients who took at
least one dose of study medication and had at
least one post baseline assessment were used in
the efficacy
analysis (intention to treat [ITT] population)
.“
Comment: although withdrawals from the
trial overall were 9/53 (17.0%), of which 4/
25 (16%) were from the terbinafine and 5/
28 (18%) were from the placebo group, the
reasons are provided and are equal between
the groups
Selective reporting (reporting bias) Unclear risk Comment: no protocol mentioned within
the paper and no protocol found on clini-
caltrials.gov
Some outcomesmentioned inmethods sec-
tion are just reported as ”not statistically
different“ in the paper but results are not
reported
Other bias (non-validated instrument) Unclear risk Quote:”CT scans were graded for extent of
opacification at baseline and end of week 6
using a modification (total opacification=50)
of the Lund-Mackay scoring system.“
Comment: unclear whether the modified
version of the Lund-Mackay scoring system
had been validated
Other bias Low risk Comment: no other sources of bias were
identified
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Liang 2008
Methods 2-arm, double-blinded, single-centre, parallel-group RCT, with 4 weeks duration of
treatment and follow-up
Participants Location: Taiwan, 1 site
Setting of recruitment and treatment: outpatient ENT clinic
Sample size: 70
• Number randomised: 36 in intervention, 34 in comparison
• Number completed: 32 in intervention, 32 in comparison
Participant (baseline) characteristics:
• Mean age (age range): group 1: 51 (17 to 75); group 2: 46 (13 to 79)
• Gender (F/M): 35 (54.7%)/29 (45.3%)
• Main diagnosis: chronic rhinosinusitis without nasal polyps
• Presence of allergic fungal rhinosinusitis: 0%
• Presence of eosinophilic CRS: not reported
• Polyps status: 0% with polyps [Exclusion criterion]
• Previous sinus surgery status: 0% [Exclusion criterion]
• Other important effect modifiers, if applicable (e.g. aspirin sensitivity,
comorbidities of asthma): none reported
Inclusion criteria: people over 12 years old with a diagnosis of CRS based on the
definition included in a report published by the Chronic Rhinosinusitis Task Force in
2003. The inclusion criteria were typical nasal symptoms for > 12weeks, nasal endoscopy
that showed mucosal swelling or purulent discharge and positive findings on sinus x-ray
films
Exclusion criteria: nasal polyps, pregnant or immunocompromised, history of sinus
surgery, or had taken antibiotics or antifungal agents within 1 week before enrolling in
the study
Interventions Intervention (n = 36): amphotericin B, 20 mg of amphotericin B in 500 mL of normal
saline, used as a nasal irrigation using a Sanvic SH903 pulsatile irrigator, 250 mL for
each nostril, once daily. Total daily dose = 20 mg amphotericin B. Treatment duration
= 4 weeks
Comparator group (n = 34): placebo (with a yellowish dye), 4 mL of placebo solution
in 500 mL of normal saline, used as a nasal irrigation using a Sanvic SH903 pulsatile
irrigator, 250 mL for each nostril, once daily. Treatment duration = 4 weeks
Use of additional interventions (common to both treatment arms):
Patients were NOT allowed to use oral antibiotics, oral antifungals, oral steroids or oral
antihistamines. Participants were also told not to use nasal sprays
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific, measured using the Chinese version
of Rhinosinusitis Outcome Measures 31 (CRSOM-31), measured at baseline, 2 weeks
and 4 weeks. Unclear range (standard RSOM-31 range is 0 to 755), lower = better
quality of life
Secondary outcomes:
• Endoscopy (overall score): nasal endoscopy scored by the Lund endoscopic system.
The endoscopic findings including oedema, discharge, polyps, crusting and scarring
were graded from 0 (normal) to 2 (severely diseased). Range 0 to 10; higher = worse.
Other outcomes reported by the study:
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• Fungal and bacterial cultures
Funding sources No information provided
Declarations of interest No information provided
Notes Non-parametric tests were used for quality of life score and endoscopic scores
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”Randomly allocated“
Comment: not enough information to de-
termine whether this was a low risk of bias
Allocation concealment (selection bias) Unclear risk Comment: not enough information to de-
termine
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”double-blind“
Comment: although there is a lack of in-
formation the paper does explain how the
placebo solution was made to look like the
amphotericin solution (addition of dye)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”double-blind“
Comment: not enough information to de-
termine whether the outcome measure of
nasal endoscopy was completed by some-
one who had knowledge of the treatment
allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: the dropout rate was low at 6/
70 (8.6%). There was no difference in the
dropout rate or reasons for dropout be-
tween the 2 groups
Selective reporting (reporting bias) Low risk Comment: no protocol could be found
on clinicaltrials.gov or the Chinese clini-
cal trial registry. Results for all outcomes as
presented in the methods sections are pre-
sented in the results as median values with
ranges
Other bias (non-validated instrument) Low risk Comment: the study used the RSOM-31
instrument for health-related quality of life
and the paper did provide the reference
to the validation paper relating to the val-
idation of the Chinese version. It is not
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clear what the scoring systemusedwas. The
Lund-Mackay endonasal scoring system is
a validated, widely used scale. References
are given for the validation papers
Other bias Low risk Comment: no additional sources of bias
were identified
Ponikau 2005
Methods 2-arm, double-blind, parallel-group RCT, with 6 months duration of treatment and
follow-up
Participants Location: USA, 1 site
Setting of recruitment and treatment: Otorhinolaryngology Department, Mayo
Sample size: 30
• Number randomised: 15 in intervention, 15 in comparison
• Number completed: 10 in intervention, 14 in comparison
Participant (baseline) characteristics:
• Age: group 1: 56.9 (16.8); group 2: 49.7 (13.2)
• Gender M (%)/F (%): 21 (70%)/9 (30%)
• Main diagnosis: chronic rhinosinusitis
• Presence of allergic fungal rhinosinusitis: not reported
• Presence of eosinophilic CRS: not reported
• Polyps status: not reported
• Previous sinus surgery status: group 1: 13 (87%); group 2: 12 (80%)
• Other important effect modifiers, if applicable:
◦ Asthma: group 1: 9 (60%); group 2: 9 (60%)
Inclusion criteria: adults > 18 years meeting the American Academy of Otorhinolaryn-
gology diagnosis of CRS. CRS symptoms for > 3 months. Demonstrated mucosal thick-
ening on coronal CT scans > 5 mm in 2 or more sinuses and on nasal endoscopy (DAS)
Exclusion criteria: acute bacterial exacerbation of CRS, acute complication of CRS,
antibiotic therapy or systemic antifungal use in last 7 days, systemic steroid use in the
last 3 months
Known hypersensitivity to amphotericin B, female patients who are pregnant or lactat-
ing, immunocompromised patients (HIV, post transplant, diabetes), acute respiratory
illnesses (within the last 7 days), acute complication of CRS (i.e. abscess), acute bacte-
rial exacerbation of CRS (acute pain, acute pressure, fever, pus on discharge), orbital or
central nervous system complications of CRS
Interventions Intervention (n = 15): 20 mL amphotericin B solution (250 µg/mL) to each nostril
twice a day by using a bulb syringe, for 6 months. Total daily dose = 20 mg amphotericin
B
Comparator group (n = 15): 20 mL sterile water placebo solution (identical in ap-
pearance to the intervention arm) to each nostril twice a day using a bulb syringe, for 6
months
Use of additional interventions (common to both treatment arms):
Both groups continued with their current treatment regimen but were instructed to
record any change
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Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific. Measured with the Sino Nasal
Outcome Test (SNOT-20), at 3 and 6 months
Secondary outcomes:
• Endoscopy: scored each side on a scale of 0 to 4, resulting in a total score of 0 to
8, at 3 and 6 months. Made by one observer. Criteria for the scoring are provided in
the paper. Measured at 3 and 6 months.
• CT scan: reduction from baseline in the percentage of inflammatory mucosal
thickening, which occluded the nasal and paranasal cavities, at 3 and 6 months.
• Adverse effects (topical antifungals): local discomfort
Other outcomes reported by the study:
• Levels of inflammatory mediators (IL-5 and eosinophil-derived neurotoxin)
• Levels of intranasal Alternaria protein
• Blood eosinophilia
Funding sources ”Supported by grants from the National Institutes of Health, R01 AI49235, and by the Mayo
Foundation for Education and Research.”
Declarations of interest “The Mayo Foundation for Education and Research owns US Patent 6,555,566 (Methods
and materials for treating and preventing inflammation of mucosal tissue). Dr Ponikau is
listed as an inventor. A license agreement has been signed with Accentia Pharmaceutical, Inc.
No other relevant conflicts exist.”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote:”The Division of Biostatistics, Mayo
Clinic Rochester (Minn), generated the ran-
domization schedule by using a block ran-
domization scheme (block size of 4). Investi-
gators were unaware of the block size.“
Comment: adequate randomisation
method
Allocation concealment (selection bias) Low risk Quote: ”Investigators were unaware of the
block size. The pharmacist produced num-
bered bottles with each patient’s study number,
containing either amphotericin B or placebo,
according to the randomization schedule.“
Comment: adequate allocation conceal-
ment
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote:”No difference in the appearance,
taste, or smell could be detected [between the
intervention and placebo solutions].“
Comment: adequate blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: [For primary outcome]”The repro-
ducibility of this method was independently
confirmed by 3 blinded investigators“
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 6/30 (20%) patients did not
complete the study. The reasons are pro-
vided but 5 were from the intervention
group and 1 from the placebo group
Selective reporting (reporting bias) Unclear risk Comment: no protocol was identified on
clinicaltrials.gov. As well as presenting the
raw results the paper presents ”percentage
improved“, which was not stated in the
methods section
No mention of how adverse effects were
measured in the methods section
Other bias (non-validated instrument) Low risk Comment: study used a validated tool
(SNOT-20) for the primary outcome
Other bias Unclear risk Comment: as a single-centre trial, there is
a possibility of selection bias and a lack of
generalisability. There were also imbalances
in age and duration of CRS between the
2 groups, but the statistical significance of
these was not reported
Shin 2004
Methods 3-arm, non-blinded, parallel-group trial (unclear randomisation), with 4 weeks duration
of treatment and follow-up
Participants Location: South Korea, single site
Setting of recruitment and treatment: Department of Otolaryngology
Sample size: 41
• Number randomised: 16 in high-dose AMB, 14 in low-dose AMB, 11 in control
• Number completed: 16 in high-dose AMB, 14 in low-dose AMB, 11 in control
Participant (baseline) characteristics:
• Mean age (years): high-dose AMB: 44.1; low-dose AMB: 38.1; control: 41.3
• Gender (M/F): high-dose AMB: 8/8; low-dose AMB: 10/4; control: 7/4
• Main diagnosis: CRS with nasal polyposis
• Presence of allergic fungal rhinosinusitis: 0% (all had negative skin prick test)
• Presence of eosinophilic CRS: not reported
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• Polyps status: 100% with polyps
• Previous sinus surgery status: not reported
• Other important effect modifiers, if applicable (e.g. aspirin sensitivity,
comorbidities of asthma): 0% with a history of allergy or asthma
Inclusion criteria: diagnosis of CRSwas based on the 1996Task Force onRhinosinusitis
criteria. CT scan of the paranasal sinuses and endoscopy was used to confirm the presence
of nasal polyps
All of the participants had a negative skin prick test and a negativemultiple allergosorbent
test chemiluminescent assay
Exclusion criteria: patients who had received systemic or topical steroids or antibiotics
or who had a history of allergy, asthma or other systemic diseases
Interventions High-dose antifungal group 1 (n = 16): amphotericin B dissolved in sterile water at a
concentration of 100 mg/L. Intranasal administration of 10 mL of the solution into each
nostril twice daily with a syringe. Total daily dose = 4 mg amphotericin B. Treatment
duration = 4 weeks
Low-dose antifungal group 2 (n = 14): amphotericin B dissolved in sterile water at a
concentration of 50 mg/L. Intranasal administration of 10 mL of the solution into each
nostril twice daily with a syringe. Total daily dose = 2 mg amphotericin B. Treatment
duration = 4 weeks
Comparator group (n = 11): normal saline, 10 mL of the solution was administered
into each nostril twice daily. Treatment duration = 4 weeks
Use of additional interventions (common to both treatment arms): none listed
Outcomes Outcomes of interest in the review:
No primary outcomes reported
No secondary outcomes reported
Other outcomes reported by the study:
Cytokine protein contents of nasal polyps (IL-5, IL-8, INF-y, RANTES)
Funding sources No information provided
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were randomly selected
based on their willingness to participate”
Comment: it is unclear if this ’randomisa-
tion’ was to the study (i.e. not an RCT) or
to the treatment group. No randomisation
methods are given
Due to a lack of information about baseline
characteristics, selection bias is possible
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Allocation concealment (selection bias) Unclear risk Comment: no information about alloca-
tion concealment. Lack of information
about baseline characteristics. Participant
selection is possible
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: the study does notmention that
it was blinded. There was a control group
but the control treatment (intranasal saline)
is likely to look different to the intervention
groups
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: the study does not mention if
the outcome assessment was blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: outcome data were available for
all participants who completed. However,
the paper does not provide information
about the number of people who were po-
tentially eligible for the trial, or who started
and did not finish
Selective reporting (reporting bias) Low risk Comment: no protocol for the trial was
available on clinicaltrials.gov or the WHO
clinical trials registry
All of the outcomes that were reported in
themethods are presented in the results sec-
tion
Other bias (non-validated instrument) Unclear risk Comment: no outcomes of interest were
reported
Other bias Low risk Comment: no other sources of bias were
identified
Weschta 2004
Methods 2-arm, double-blind, single-centre, parallel-group RCT, with 8 weeks duration of treat-
ment and follow-up
Participants Location: Germany, 1 site
Setting of recruitment and treatment: Department of Otorhinolaryngology and Head
and Neck Surgery
Sample size: 78
• Number randomised: 39 in intervention, 39 in comparison
• Number completed: 28 in intervention, 32 in comparison
Participant (baseline) characteristics:
• Median age (range) years: AMB: 54 (37 to 67); control: 48 (25 to 77)
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• Gender (M (%)/F (%)): 40 (66.7%)/20 (33.3%) (Note: imbalance in females
between groups AMB: 23/5; control: 17/15)
• Main diagnosis: patients CRS with nasal polyps referred for paranasal sinus
surgery
• Presence of allergic fungal rhinosinusitis: 0% with AFRS (exclusion criterion)
• Polyps status: 100% with polyps; mean polyp score not reported
• Previous sinus surgery status: AMB: 61%; control: 50%
• Other important effect modifiers:
◦ Positive skin prick test to common allergens: AMB: 14%; control: 16%
◦ Acetylsalicylic acid intolerance: AMB: 14%; control: 25%
◦ Bronchial asthma: AMB: 29%; control: 25%
◦ Corticosteroid use (topical or systemic): AMB: 61%; control: 50%
Inclusion criteria: 1)age > 18 years, 2) recent CT scan of paranasal sinuses, 3) symptom
score > 14 (max 30), 4) endoscopy score > 2 (max 6), 5) CT score > 19 (max 40)
Exclusion criteria:1) current participation in other clinical study, 2) pregnancy or breast-
feeding, 3) mental impairment or severe illnesses, 4) hypersensitivity to study medica-
tion, 5) history of immotile cilia syndrome or cystic fibrosis, 6) urgent need for or recent
paranasal surgery, 7) recent start on specific antiallergic immunotherapy, corticosteroid
therapy, antihistamines, acetylsalicylic acid desensitisation, 8) discontinuous study med-
ication intake, 9) antimycotic or immunosuppressive therapy, 9) clinical suspicion of
AFRS
Interventions Intervention (n = 39): amphotericin B (3 mg/mL), nasal spray, 2 puffs per nostril (200
µLper nostril), 4 times daily. Total daily dose = 4.8mg amphotericin. Treatment duration
= 8 weeks
Comparator group (n = 39): control nasal spray: saline solution containing tartrazine,
chinin sulfate, 1-(4-sulfo-1-phenylazo)-2-naphthol-6-sulfo acid, choline in 5% glucose
solution, 2 puffs per nostril, 4 times daily. Treatment duration = 8 weeks
Use of additional interventions (common to both treatment arms):
Patients were allowed to continue with medication as before providing the dose was
stable. Topical or systemic corticosteroids were used by 61% in the intervention and
50% in the control group
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific: ”rhinosinusitis quality of life score
(RQL)“ modified by authors from another instrument (6 questions measured on a 7-
point scale (0 to 6); range 0 to 36; higher = worse). Time point = 8 weeks.
• Disease severity symptom score (symptoms of nasal blockage, facial pain, smell
disturbance, nasal discharge and sneezing. Each measure on a 10 cm visual analogue
scale, higher = worse). Time point = 8 weeks.
Secondary outcomes:
• Endoscopy (polyps size or overall score; range 0 to 6; higher = worse). Time point
= 8 weeks.
• CT scan (Lund-Mackay score, range 0 to 40; higher = worse). Time point = 8
weeks.
• Adverse effects (topical antifungals): epistaxis, headache, local discomfort
• Adverse effects (systemic antifungals): gastrointestinal disturbances, allergic
reactions
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Weschta 2004 (Continued)
Other outcomes reported by the study:
• Response rate: defined as 50% reduction of pre-treatment CT score
• Detection of fungal elements
Funding sources No information provided
Declarations of interest No information provided
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Patients were randomly allocated to
the 2 treatment arms by the Department of
Biometry andMedical Documentation, Uni-
versity of Ulm.“
Comment: no further information pro-
vided about method of randomisation
Allocation concealment (selection bias) Unclear risk Comment: no mention of methods used to
conceal allocation of patients. It does men-
tion that healthcare professionals were kept
blind to the treatment allocation until the
end of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”Active drug and control sprays were
manufactured by the pharmacy of the Uni-
versity Hospital of Ulm. They were indistin-
guishable in color, taste, smell, and nasal sen-
sations during application.“
”To assure blinding of investigators, the mild
irritant chinin sulfate was added to the con-
trol spray. Neither patients nor investigators
were aware of the kind of treatment during
the entire study period.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: although this is not discussed in
detail, the flow chart on page 1124 clearly
shows that ”unblinding“ occurred after the
data analysis was completed
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 15/39 (38%) participants
dropped out from the intervention arm; 7/
39 (18%) dropped out of the control arm.
Reasons for the dropouts were provided;
most in the intervention group were due to
intolerance of the study medication
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Weschta 2004 (Continued)
Selective reporting (reporting bias) Unclear risk Comment: the protocol for the study could
not be identified through clinicaltrials.gov
or the European trials registry. All of the
outcomes as reported in the methods sec-
tion were reported in the results section
although for some only vague figures are
given. For example, for endoscopic score
the paper states ”The median endoscopy
scores were almost identical in the AMB and
control groups (4 vs 4) and did not change
remarkably after treatment.“
A big difference in adverse effects between
the groups is reported but details of the
events and the number of patients is not
provided
Other bias (non-validated instrument) Unclear risk Comment: for disease-specific quality of
life the study modified an existing ques-
tionnaire developed for patients with al-
lergy - the mini Rhinoconjunctivitis Qual-
ity of Life Questionnaire (mRQLQ) ”rhi-
nosinusitis quality of life score (RQL)“.
However, the paper does not provide any
link to any validation of the modified in-
strument, and no publications on the val-
idation of the RQL were found by the re-
view authors. The remaining instruments
used were well-accepted, validated instru-
ments (Lund Mackay, VAS used for symp-
toms)
Other bias Unclear risk Comment: baseline characteristics were
balanced with the exception of gender. The
procedure for additional recruitment of pa-
tients to compensate for dropouts was not
reported
AFRS: allergic fungal rhinosinusitis
ALT: alanine aminotransferase
AMB: amphotericin B
ARS: acute rhinosinusitis
AST: aspartate aminotransferase
CT: computerised tomography
CRS: chronic rhinosinusitis
ENT: ear, nose and throat
ESS: endoscopic sinus surgery
F: female
GGT: gamma-glutamyl transpeptidase
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IM: intramuscular
LAS: lysine acetylsalicylate
M: male
NP: nasal polyps
RANTES: regulated on activation, normal T cell expressed and secreted
RCT: randomised controlled trial
RSOM-31: Rhinosinusitis Outcome Measure-31
SD: standard deviation
SNOT-20: Sino-Nasal Outcome Test-20
VAS: visual analogue scale
WHO: World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chan 2008 STUDY DESIGN:
Case series
Gerlinger 2009 POPULATION:
Post-surgical population - all participants underwent surgery at the start of the trial
Gupta 2007 POPULATION:
Post-surgical population - all participants had surgery at the start of the trial prior to randomisation
Hashemi 2014 STUDY DESIGN:
Case series
Helbling 2006 STUDY DESIGN:
Case series
Hofman 2004 STUDY DESIGN:
Case series
IRCT138706101138N1 POPULATION:
Post-surgical population - all patients underwent surgery at the start of the trial
Jiang 2015 POPULATION:
Post-surgical population - all patients underwent surgery 1 month prior to randomisation (6-week limit)
Joshi 2007 STUDY DESIGN:
Case series
Khalil 2011 POPULATION:
Post-surgical population - all patients underwent surgery at the start of the trial
Lopatin 2007 POPULATION:
Post-surgical population - all patients underwent surgery at the start of the trial
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(Continued)
NCT02285283 POPULATION:
Post-surgical population - all patients will undergo surgery. Clinical trial protocol - no information
regarding whether this trial has completed
Nikakhlagh 2015 POPULATION:
Post-surgical population - all participants underwent surgery before the start of the trial (within 6 weeks)
Panda 2012 POPULATION:
Post-surgical population - all patients underwent surgery at the start of the trial
Patro 2015 COMPARISON:
All participants in the control group underwent surgery immediately
Ravikumar 2011 POPULATION:
Post-surgical population - all participants underwent surgery as part of the trial
Ricchetti 2002 STUDY DESIGN:
Non-randomised trial
Ricchetti 2002b STUDY DESIGN:
Case series
Rojita 2017 POPULATION:
Post-surgical population - all patients underwent surgery at the start of the trial
Somu 2015 POPULATION:
Post-surgical population - all patients underwent surgery during the trial
Thamboo 2011 STUDY DESIGN:
Randomised by side of nose
INTERVENTION:
Honey (with antimicrobial and antifungal properties)
Verma 2016 POPULATION:
Control group underwent immediate surgery. No pre-operative comparisons were made
Zhang 2012 POPULATION:
Post-surgical population - all patients underwent surgery during the trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Deka 2007
Methods Prospective randomised controlled trial
Participants 88 patients with allergic fungal sinusitis
Interventions Group 1: amphotericin B nasal lavage and corticosteroid nasal spray; Group 2: corticosteroid nasal spray alone
Outcomes Improvement of nasal symptoms, nasal endoscopy score
Notes Abstract only. Contacted authors for more information but no response was received. Abstract published in 2007; it
is unlikely that this study will be published in full
Frigas 2007
Methods Prospective, double-blind, placebo-controlled trial
Participants 8 patients with chronic rhinosinusitis and mild asthma
Interventions Group 1: 200 mg of itraconazole, twice daily for 4 weeks; Group 2: placebo tablets, twice daily for 4 weeks
Outcomes Chronic rhinosinusitis symptoms, sinus CT scan
Notes Abstract only. Contacted authors for more information but no response was received. Abstract published in 2007; it
is unlikely that this study will be published in full
Lopatin 2004
Methods Unclear
Participants -
Interventions -
Outcomes -
Notes Abstract only; it is unlikely that this study will be published in full. Unable to obtain the full abstract - title of paper
only
Stergiou 2007
Methods Prospective randomised controlled trial
Participants Chronic sinusitis
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Stergiou 2007 (Continued)
Interventions Group 1: amphotericin B suspension; Group 2: placebo solution
Treatment duration = 4 months
Outcomes Chronic rhinosinusitis symptoms
Notes Registered protocol and abstract of trial protocol only. Trial protocol was last updated in 2007 and no results are
provided. Unclear if patients all underwent surgery at the start of the trial
CT: computerised tomography
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D A T A A N D A N A L Y S E S
Comparison 1. Topical antifungal versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Generic HRQL (change from
baseline)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Physical component 1 116 Mean Difference (IV, Fixed, 95% CI) -0.80 [-3.66, 2.06]
1.2 Mental component 1 116 Mean Difference (IV, Fixed, 95% CI) -2.20 [-5.46, 1.06]
2 Adverse effects - epistaxis 4 225 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.14, 6.63]
3 Adverse effects - headache 3 195 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.60, 2.63]
4 Adverse effects - local irritation 5 312 Risk Ratio (M-H, Fixed, 95% CI) 2.29 [0.61, 8.62]
5 CT score 1 48 Std. Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.79, 0.34]
Comparison 2. Systemic antifungal versus placebo/no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe adverse effects - hepatic
toxicity
1 53 Risk Ratio (M-H, Fixed, 95% CI) 3.35 [0.14, 78.60]
2 Adverse effects - gastrointestinal
disturbances
1 53 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.04, 3.36]
3 CT score - opacification %
change from baseline
1 49 Mean Difference (IV, Fixed, 95% CI) -0.14 [-19.22, 18.
94]
4 CT score - obstruction score %
change from baseline
1 47 Mean Difference (IV, Fixed, 95% CI) -4.4 [-40.12, 31.32]
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Analysis 1.1. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 1 Generic HRQL
(change from baseline).
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 1 Topical antifungal versus placebo/no treatment
Outcome: 1 Generic HRQL (change from baseline)
Study or subgroup Topical antifungal Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Physical component
Ebbens 2006 59 0.6 (7.1) 57 1.4 (8.5) 100.0 % -0.80 [ -3.66, 2.06 ]
Subtotal (95% CI) 59 57 100.0 % -0.80 [ -3.66, 2.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Mental component
Ebbens 2006 59 -0.3 (8.1) 57 1.9 (9.7) 100.0 % -2.20 [ -5.46, 1.06 ]
Subtotal (95% CI) 59 57 100.0 % -2.20 [ -5.46, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
-50 -25 0 25 50
Favours placebo Favour topical antifungal
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Analysis 1.2. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 2 Adverse effects -
epistaxis.
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 1 Topical antifungal versus placebo/no treatment
Outcome: 2 Adverse effects - epistaxis
Study or subgroup Topical antifungal Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Corradini 2006 0/25 0/23 Not estimable
Ebbens 2006 2/59 2/57 100.0 % 0.97 [ 0.14, 6.63 ]
Ponikau 2005 0/15 0/15 Not estimable
Shin 2004 0/20 0/11 Not estimable
Total (95% CI) 119 106 100.0 % 0.97 [ 0.14, 6.63 ]
Total events: 2 (Topical antifungal), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favour topical antifungal Favours no antifungal
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Analysis 1.3. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 3 Adverse effects -
headache.
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 1 Topical antifungal versus placebo/no treatment
Outcome: 3 Adverse effects - headache
Study or subgroup Topical antifungal Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Corradini 2006 0/25 0/23 Not estimable
Ebbens 2006 13/59 10/57 100.0 % 1.26 [ 0.60, 2.63 ]
Shin 2004 0/20 0/11 Not estimable
Total (95% CI) 104 91 100.0 % 1.26 [ 0.60, 2.63 ]
Total events: 13 (Topical antifungal), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favour topical antifungal Favours no antifungal
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Analysis 1.4. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 4 Adverse effects -
local irritation.
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 1 Topical antifungal versus placebo/no treatment
Outcome: 4 Adverse effects - local irritation
Study or subgroup Topical antifungal Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Corradini 2006 0/25 0/23 Not estimable
Ebbens 2006 0/59 1/57 50.2 % 0.32 [ 0.01, 7.75 ]
Hashemian 2016 2/24 0/24 16.5 % 5.00 [ 0.25, 98.96 ]
Liang 2008 1/36 0/34 16.9 % 2.84 [ 0.12, 67.36 ]
Ponikau 2005 2/15 0/15 16.5 % 5.00 [ 0.26, 96.13 ]
Total (95% CI) 159 153 100.0 % 2.29 [ 0.61, 8.62 ]
Total events: 5 (Topical antifungal), 1 (Placebo)
Heterogeneity: Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favour topical antifungal Favours no antifungal
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Analysis 1.5. Comparison 1 Topical antifungal versus placebo/no treatment, Outcome 5 CT score.
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 1 Topical antifungal versus placebo/no treatment
Outcome: 5 CT score
Study or subgroup Antifungal
placebo/no
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hashemian 2016 24 13.58 (7.18) 24 15.21 (7.1) 100.0 % -0.22 [ -0.79, 0.34 ]
Total (95% CI) 24 24 100.0 % -0.22 [ -0.79, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours antifungal Favours no antifungal
Analysis 2.1. Comparison 2 Systemic antifungal versus placebo/no treatment, Outcome 1 Severe adverse
effects - hepatic toxicity.
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 2 Systemic antifungal versus placebo/no treatment
Outcome: 1 Severe adverse effects - hepatic toxicity
Study or subgroup Topical antifungal
Placebo/no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kennedy 2005 1/25 0/28 100.0 % 3.35 [ 0.14, 78.60 ]
Total (95% CI) 25 28 100.0 % 3.35 [ 0.14, 78.60 ]
Total events: 1 (Topical antifungal), 0 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favour topical antifungal Favours placebo
66Topical and systemic antifungal therapy for chronic rhinosinusitis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Systemic antifungal versus placebo/no treatment, Outcome 2 Adverse effects -
gastrointestinal disturbances.
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 2 Systemic antifungal versus placebo/no treatment
Outcome: 2 Adverse effects - gastrointestinal disturbances
Study or subgroup Topical antifungal
Placebo/no
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kennedy 2005 1/25 3/28 100.0 % 0.37 [ 0.04, 3.36 ]
Total (95% CI) 25 28 100.0 % 0.37 [ 0.04, 3.36 ]
Total events: 1 (Topical antifungal), 3 (Placebo/no treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favour topical antifungal Favours no antifungal
Analysis 2.3. Comparison 2 Systemic antifungal versus placebo/no treatment, Outcome 3 CT score -
opacification % change from baseline.
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 2 Systemic antifungal versus placebo/no treatment
Outcome: 3 CT score - opacification % change from baseline
Study or subgroup Antifungal
Placebo/no
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kennedy 2005 23 -7.2 (33.3) 26 -7.06 (34.8) 100.0 % -0.14 [ -19.22, 18.94 ]
Total (95% CI) 23 26 100.0 % -0.14 [ -19.22, 18.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours no antifungal Favours antifungal
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Analysis 2.4. Comparison 2 Systemic antifungal versus placebo/no treatment, Outcome 4 CT score -
obstruction score % change from baseline.
Review: Topical and systemic antifungal therapy for chronic rhinosinusitis
Comparison: 2 Systemic antifungal versus placebo/no treatment
Outcome: 4 CT score - obstruction score % change from baseline
Study or subgroup Antifungal
Placebo/no
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kennedy 2005 21 2.3 (49.8) 26 6.7 (74.6) 100.0 % -4.40 [ -40.12, 31.32 ]
Total (95% CI) 21 26 100.0 % -4.40 [ -40.12, 31.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours no antifungal Favours antifungal
A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Ref ID Population Intervention Adjuvant
treatment
Inclusion (n) Polyps AFRS Intervention Method of deliv-
ery
Treatment dura-
tion
Corradini
2006
(Italy)
Nasal polyps +
positive fungal
infection
(48)
100% 0% Amphotericin B
(3 mg/mL)
Inhala-
tion: 0.24 mL/day
6 times per week
for 1month (daily
total = 0.8 mg
AMB)
0.16
mL/day 6 times
per week for un-
defined time (to-
tal daily dose = 0.
5 mg AMB)
Undefined - 19
months?
Medical polypec-
tomy and lysine
acetylsali-
cylate (NSAID) 4
mg/day
Ebbens 2006
(Belgium,
UK, Spain,
Netherlands)
Chronic rhi-
nosinusitis ±
nasal polyps
(116)
82%% 0% Amphotericin B
(0.1 mg/mL)
Irrigation: 25 mL
solution ap-
plied to each nos-
tril twice daily us-
13 weeks Antibiotics, INCS
and systemic
steroids were al-
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Table 1. Summary of study characteristics (Continued)
ing
an Emcur (Rhini-
cur) nasal douch-
ing device (total
daily dose = 10mg
AMB)
lowed, with re-
strictions. 68% of
participants used
INCS
Hashemian
2016
(Iran)
Chronic rhi-
nosinusitis
± nasal polyps
unresponsive
to treatment
(54)
44% NR Fluconazole
(2 mg/mL (0.2%)
)
Nasal drops:
2 mg/mL (6 drops
per day, 2 times
a day) (total daily
dose = 1.2 mg flu-
conazole)
8 weeks All patients
used INCS (fluti-
casone)
Liang 2008
(Taiwan)
Chronic rhi-
nosinusitis
without nasal
polyps (70)
0% NR Amphotericin B
(0.04 mg/mL)
Irrigation:
250mL (0.04mg/
mL solution) in
each nostril once
daily using a San-
vic SH903 pul-
satile irrigator (to-
tal daily dose = 20
mg AMB)
4 weeks No adjunct treat-
ment was allowed
Ponikau 2005
(USA)
Chronic rhi-
nosinusi-
tis unrespon-
sive to treat-
ment
(30)
100% with
positive fungal
culture
NR NR Amphotericin B
(0.25 mg/mL)
Irrigation: 20 mL
(0.25 mg/mL so-
lution) in each
nostril twice daily
using a bulb sy-
ringe (total daily
dose = 20 mg
AMB)
6 months Participants con-
tinued
with current treat-
ment regimen
(50% used INCS)
Shin 2004
(South Korea)
Chronic rhi-
nosinusitis pa-
tients with
nasal polyps
(41)
100% 0% Amphotericin B
(high: 0.1 mg/
mL; low: 0.05mg/
mL)
Irrigation: 10 mL
of the solution
into each nostril
twice daily with a
syringe
High-dose:
0.1 mg/mL (total
daily dose = 4 mg
AMB)
Low-
dose 0.05 mg/mL
(total daily total =
2 mg AMB)
4 weeks Not reported
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Table 1. Summary of study characteristics (Continued)
Weschta 2004
(Germany)
Chronic rhi-
nosinusi-
tis with nasal
polyps
referred for
surgery
(78)
100% 0% Amphotericin B
(3 mg/mL)
Nasal spray:
2 puffs per nostril
(0.2 mL per nos-
tril), 4 times daily
(total daily dose =
4.8 mg)
8 weeks Participants con-
tinued
with current treat-
ment regimen
(40% used INCS)
Systemic antifungals
Kennedy
2005
(USA)
Chronic rhi-
nosinusi-
tis unrespon-
sive to treat-
ment
(53)
77% with
positive fungal
culture
NR NR Terbinafine Oral: 625 mg/day 6 weeks Participants con-
tinued with
current treatment
regimen - regimen
was kept consis-
tent
AFRS: allergic fungal rhinosinusitis; AMB: amphotericin B; INCS: intranasal corticosteroids; NR: not reported
None of the studies reported eosinophilic chronic rhinosinusitis status.
Table 2. Summary of disease severity score results
Ref ID Instrument details How reported
(time point)
Results Difference between
groups
NotesAntifungal Placebo
Topical antifungals
Ebbens 2006 RSOM-31
Range: 0 to 775a
Lower score = better
QOL
Change from base-
line
(13 weeks)
Baseline: 150
Mean change: 17.0
SD: 86.4
N: 59
Baseline: 176
Mean change: -3.6
SD: 100.4
N: 57
P = 0.35
Small relative
changes (17 and 3.6
points on a scale of 0
to 775)
Hashemian 2016 SNOT-20
Range: 0 to 100
Lower score = better
QOL
Endpoint
(8 weeks)
Baseline: 36.29
After treatment: 27.
25
SD: 15.88
N: 24
Baseline: 41.33
After treatment: 28.
71
SD: 18.24
N: 24
P = 0.76
Large
SD values compared
to mean may be an
indication that the
data are skewed
Liang 2008 Chinese RSOM-31
Range: 0 to 775a
Lower score = better
QOL
Endpoint
(4 weeks)
Median baseline:
201.5
Median after treat-
Median baseline:
227
Median after treat-
P = 0.091
Un-
equal distribution of
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Table 2. Summary of disease severity score results (Continued)
ment: 65.5
Range: 10 to 466
N: 32
ment: 121.5
Range: 8 to 405
N: 32
median within the
range values indicate
the data are likely to
be skewed
Ponikau 2005 SNOT-20
Range: 0 to 5
Lower score = better
QOL
Change from base-
line
(6 months)
Median baseline: 2.3
Median change:
-0.3
Range: -1.3 to 0.3
N: 10
Median baseline: 1.8
Median change:
-0.3
Range: -1.8 to 0.8
N: 14
P = 0.72
Data reported asme-
dians and ranges in-
dicating possibility
of skewed data, al-
though the median
appears to sit inmid-
dle of range values
Systemic antifungals
Kennedy 2005 Rhinosinusitis Dis-
ability Index (RSDI)
Range: 0 to 120
Lower score = better
QOL
Unclear
(9 weeks)
Values for the results were not given Authors state that
“no differences were
observed” at any time
point measured
IQR: interquartile ranges; N: number of participants; QOL: quality of life; RSOM-31: Rhinosinusitis Outcome Measure-31; SD:
standard deviation; SNOT-20: Sino-Nasal Outcome Test-20
a) The range is not explicitly stated in the paper but is assumed to be from 0 to 775, which is the general range for the RSOM-31
instrument including the importance scale.
b) The range is not explicitly stated in the paper but is the standard range for the RSDI instrument.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
CENTRAL (via CRS Web) MEDLINE (Ovid) Embase (Ovid) Web of Science (Web of
Knowledge)
#1
MESH DESCRIPTOR Rhini-
tis EXPLODE ALL TREES
#2 MESH DESCRIP-
TOR Paranasal Sinus Diseases
EXPLODE All TREES
1 exp Rhinitis/
2 exp Paranasal Sinuses/
3 exp Paranasal Sinus Diseases/
4 (rhinosinusitis or nasosinusi-
tis or pansinusitis or ethmoidi-
tis or sphenoiditis).ab,ti
1 exp rhinitis/
2 exp Paranasal Sinuses/
3 exp Paranasal Sinus Diseases/
4 (rhinosinusitis or nasosinusi-
tis or pansinusitis or ethmoidi-
tis or sphenoiditis).ab,ti
S1 TOPIC: ((rhinosinusitis or
nasosinusitis or pansinusitis or
ethmoiditis or sphenoiditis))
S2 TOPIC: ((kartagener* near/
3 syndrome*))
S3 TOPIC: ((inflamm* near/3
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#3 MESH DE-
SCRIPTOR Paranasal Sinuses
EXPLODE All TREES
#4 (rhinosinusitis or nasosi-
nusitis or pansinusitis or eth-
moiditis or sphenoiditis):TI,
AB,KY
#5 (kartagener* near
syndrome*):TI,AB,KY
#6 (inflamm* near sinus*):TI,
AB,KY
#7 ((maxilla* or frontal*) near
sinus*):TI,AB,KY
#8 #1 OR #2 OR #3 OR #4
OR #5 OR #6 OR #7
#9 MESH
DESCRIPTOR Chronic Dis-
ease EXPLODE All TREES
#10
MESH DESCRIPTOR Recur-
rence EXPLODE All TREES
#11 MESH DESCRIPTOR
Fungi EXPLODE All TREES
#12
MESH DESCRIPTOR Myce-
toma EXPLODE All TREES
#13 (chronic or persis* or re-
current* or fung* or eosinophil*
or mycetoma* or Maduromy-
cos* or Actinomycetoma* or
Eumycetoma*):TI,AB,KY
#14 #9 OR #10 OR #11 OR #
12 OR #13
#15 #8 AND #14
#16 (CRSsNPor AFS or AFRS)
:TI,AB,KY
#17 ((sinusitis or rhinitis) near
(chronic or persis* or recurrent*
or fung*)):TI,AB,KY
#18 #15 OR #16 OR #17
#19 MESH DESCRIPTOR
Nasal Polyps EXPLODE All
TREES
#20 MESH DESCRIPTOR
Paranasal Sinus Diseases EX-
PLODE ALL TREES WITH
QUALIFIERS MI
#21 MESH DESCRIP-
TOR Rhinitis EXPLODE ALL
5 (kartagener* adj3 syndrome*)
.ab,ti.
6 (inflamm* adj3 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 si-
nus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp Chronic Disease/
10 exp Recurrence/
11 exp Fungi/
12 exp Mycetoma/
13 (chronic or persis* or recur-
rent* or fung* or eosinophil*
or mycetoma* or Maduromy-
cos* or Actinomycetoma* or
Eumycetoma*).ab,ti
14 9 or 10 or 11 or 12 or 13
15 8 and 14
16 (CRSsNP or AFS or AFRS)
.ab,ti.
17 ((sinusitis or rhinitis) adj3
(chronic or persis* or recurrent*
or fung*)).ab,ti
18 15 or 16 or 17
19 exp Nasal Polyps/
20 exp Paranasal Sinus Dis-
eases/mi [Microbiology]
21 exp rhinitis/mi [Microbiol-
ogy]
22 exp Nasal Mucosa/mi [Mi-
crobiology]
23 exp Paranasal Sinuses/mi
[Microbiology]
24 exp Nose/
25 exp Nose Diseases/
26 24 or 25
27 exp Polyps/
28 26 and 27
29 ((nose or nasal or rhino* or
rhinitis or sinus* or sinonasal)
adj3 (papilloma* or polyp* or
fung*)).ab,ti
30 (rhinopolyp* or CRSwNP).
ab,ti.
31 18 or 19 or 20 or 21 or 22
or 23 or 28 or 29 or 30
32 exp Antifungal Agents/ or
exp Amphotericin B/ or exp
Antimycin A/ or exp Azaser-
5 (kartagener* adj3 syndrome*)
.ab,ti.
6 (inflamm* adj3 sinus*).ab,ti.
7 ((maxilla* or frontal*) adj3 si-
nus*).ab,ti.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp Chronic Disease/
10 exp Recurrence/
11 exp Fungi/
12 exp Mycetoma/
13 (chronic or persis* or recur-
rent* or fung* or eosinophil*
or mycetoma* or Maduromy-
cos* or Actinomycetoma* or
Eumycetoma*).ab,ti
14 9 or 10 or 11 or 12 or 13
15 8 and 14
16 (CRSsNP or AFS or AFRS)
.ab,ti.
17 ((sinusitis or rhinitis) adj3
(chronic or persis* or recurrent*
or fung*)).ab,ti
18 15 or 16 or 17
19 exp Nasal Polyps/
20 exp Nose/
21 exp Nose Diseases/
22 20 or 21
23 exp Polyps/
24 22 and 23
25 ((nose or nasal or rhino* or
rhinitis or sinus* or sinonasal)
adj3 (papilloma* or polyp* or
fung*)).ab,ti
26 (rhinopolyp* or CRSwNP).
ab,ti.
27 18 or 19 or 24 or 25 or 26
28 exp Antifungal Agents/
29 exp Amphotericin B/
30 exp Antimycin A/
31 exp Azaserine/
32 exp Benzoates/
33 exp Brefeldin A/
34 exp Candicidin/
35 exp Cerulenin/
36 exp Clotrimazole/
37 exp Cycloheximide/
38 exp Cyclosporine/
39 exp Dichlorophen/
sinus*))
S4TOPIC: ((maxilla* near/3 si-
nus*))
S5 TOPIC: ((frontal* near/3 si-
nus*))
S6 #5OR#4OR#3OR#2OR
#1
S7 TOPIC: ((chronic or per-
sis* or recurrent* or fung* or
eosinophil* or mycetoma* or
Maduromycos* or Actinomyce-
toma* or Eumycetoma*))
S8 #7 AND #6
S9 TOPIC: (CRSsNP or AFS
or AFRS)
S10 TOPIC: (sinusitis near/3
chronic)
S11 TOPIC: (sinusitis near/3
persis*)
S12 TOPIC: (sinusitis near/3
recurrent*)
S13 TOPIC: (sinusitis near/3
fung*)
S14 TOPIC: (rhinitis near/3
fung*)
S15TOPIC: (rhinitis near/3 re-
current*)
S16 TOPIC: (rhinitis near/3
persis*)
S17 TOPIC: (rhinitis near/3
chronic)
S18 #17 OR #16 OR #15 OR
#14 OR #13 OR #12 OR #11
OR #10 OR #9 OR #8
S19 TOPIC: (nose near/3 pa-
pilloma*)
S20 TOPIC: (nose near/3
polyp*)
S21 TOPIC: (nose near/3
fung*)
S22 TOPIC: (nasal near/3
fung*)
S23 TOPIC: (nasal near/3
polyp*)
S24 TOPIC: (nasal near/3 pa-
pilloma*)
S25 TOPIC: (rhino* near/3 pa-
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TREES WITH QUALIFIERS
MI
#22 MESH DESCRIPTOR
Paranasal Sinuses EXPLODE
ALL TREES WITH QUALI-
FIERS MI
#23 MESH DESCRIPTOR
Nasal Mucosa EXPLODE ALL
TREES WITH QUALIFIERS
MI
#24 MESH DESCRIPTOR
Nose EXPLODE ALL TREES
#25 MESH DESCRIPTOR
Nose Diseases EXPLODE ALL
TREES
#26 #24 OR #25
#27
MESH DESCRIPTOR Polyps
EXPLODE ALL TREES
#28 #26 AND #27
#29 (rhinopolyp* or CRSwNP)
:TI,AB,KY
#30 ((nose or nasal or rhino* or
rhinitis or sinus* or sinonasal)
near (papilloma* or polyp* or
fung*)):TI,AB,KY
#31 #18 OR #19 OR #20 OR
#21 OR #22 OR #23 OR #28
OR #29 OR #30
#32 MESH DESCRIPTOR
Antifungal Agents EXPLODE
All TREES
#33 (antifung* or ”anti fung*“
or fungastic or fungicidal or
Fungizone or Amphocil or
Zonal or Diflucan or Triflucan
or hexal or Fluco* or Flunazul
or Fungata or Lavisa or Loitin
or Neofomiral or oxifungol or
Solacap or 49858 of BÈagyne or
51211 or Sporanox orOrungal)
:TI,AB,KY
#34 MESH DESCRIP-
TORMycoses EXPLODEALL
TREES WITH QUALIFIERS
DT,TH
#35 MESH DESCRIPTOR
Venturicidins EXPLODE All
TREES
ine/ or exp Benzoates/ or exp
Brefeldin A/ or exp Candi-
cidin/ or exp Cerulenin/ or
expClotrimazole/ or expCyclo-
heximide/ or exp Cyclosporine/
or exp Dichlorophen/ or exp
Echinocandins/ or exp Econa-
zole/ or exp Filipin/ or exp Flu-
conazole/ or exp Flucytosine/ or
exp Griseofulvin/ or exp Hex-
etidine/ or exp Itraconazole/
or exp Ketoconazole/ or exp
Lucensomycin/ or exp Mepar-
tricin/ or exp Miconazole/ or
exp Monensin/ or exp My-
cobacillin/ or exp Natamycin/
or exp Nifuratel/ or exp Nys-
tatin/ or exp Pentamidine/ or
exp Rutamycin/ or exp Salicylic
Acid/ or exp Sirolimus/ or exp
Sodium Benzoate/ or exp Thy-
mol/ or exp Tomatine/ or exp
Tolnaftate/ or exp Triacetin/ or
exp Trimetrexate/ or exp Ventu-
ricidins/
33 exp Mycoses/dt, th [Drug
Therapy, Therapy]
34 (acivicin or ajoene or
amorolfin or Amphotericin or
anidulafungin or Antimycin or
artemether or aureobasidin or
Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole).ab,ti,
nm
35 (Candicidin or candidin or
captax or caspofungin or Ceru-
lenin or ciclopirox or cilofun-
gin or Clotrimazole or com-
pactin or cordycepin or cryp-
tophycin or Cycloheximide or
Cyclosporine or (decanoic adj3
acid) or (diallyl adj3 trisulfide)
or Dichlorophen or diucifon or
echinocandin or Echinocandins
or Econazole or Ethonium or
fenticonazole or ferroin or Fil-
40 exp Echinocandins/
41 exp Econazole/
42 exp Filipin/
43 exp Fluconazole/
44 exp Flucytosine/
45 exp Griseofulvin/
46 exp Hexetidine/
47 exp Itraconazole/
48 exp Ketoconazole/
49 exp Lucensomycin/
50 exp Mepartricin/
51 exp Miconazole/
52 exp Monensin/
53 exp Mycobacillin/
54 exp Natamycin/
55 exp Nifuratel/
56 exp Nystatin/
57 exp Pentamidine/
58 exp Rutamycin/
59 exp Salicylic Acid/
60 exp Sirolimus/
61 exp Sodium Benzoate/
62 exp Thymol/
63 exp Tomatine/
64 exp Tolnaftate/
65 exp Triacetin/
66 exp Trimetrexate/
67 exp Venturicidins/
68 exp mycosis/dt, th [Drug
Therapy, Therapy]
69 (acivicin or ajoene or
amorolfin or Amphotericin or
anidulafungin or Antimycin or
artemether or aureobasidin or
Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole).tw
70 (Candicidin or candidin or
captax or caspofungin or Ceru-
lenin or ciclopirox or cilofun-
gin or Clotrimazole or com-
pactin or cordycepin or cryp-
tophycin or Cycloheximide or
Cyclosporine or (decanoic adj3
acid) or (diallyl adj3 trisulfide)
or Dichlorophen or diucifon or
echinocandin or Echinocandins
pilloma*)
S26 TOPIC: (rhino* near/3
polyp*)
S27 TOPIC: (rhino* near/3
fung*)
S28 TOPIC: (rhinitis near/3
fung*)
S29 TOPIC: (rhinitis near/3
polyp*)
S30 TOPIC: (rhinitis near/3
papilloma*)
S31 TOPIC: (sinus* near/3 pa-
pilloma*)
S32 TOPIC: (sinus* near/3
polyp*)
S33 TOPIC: (sinus* near/3
fung*)
S34 TOPIC: (sinonasal near/3
fung*)
S35 TOPIC: (sinonasal near/3
polyp*)
S36 TOPIC: (sinonasal near/3
papilloma*)
S37 TOPIC: (rhinopolyp* or
CRSwNP)
S38 #37 OR #36 OR #35 OR
#34 OR #33 OR #32 OR #31
OR #30 OR #29 OR #28 OR
#27 OR #26 OR #25 OR #24
OR #23 OR #22 OR #21 OR
#20 OR #19 OR #18
S39 TOPIC: (acivicin or ajoene
or amorolfin or Amphotericin
or anidulafungin or Antimycin
or artemether or aureobasidin
or Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole)
S40 TOPIC: (Candicidin or
candidin or captax or caspofun-
gin or Cerulenin or ciclopirox
or cilofungin or Clotrimazole
or compactin or cordycepin or
cryptophycin orCycloheximide
or Cyclosporine)
S41 TOPIC: (decanoic near/3
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#36 MESH DESCRIPTOR
Trimetrexate EXPLODE All
TREES
#37 MESH DESCRIP-
TOR Triacetin EXPLODE All
TREES
#38 MESH
DESCRIPTOR Tolnaftate EX-
PLODE All TREES
#39
MESH DESCRIPTOR Toma-
tine EXPLODE All TREES
#40 MESH DESCRIP-
TOR Thymol EXPLODE All
TREES
#41 MESH DESCRIPTOR
Sodium Benzoate EXPLODE
All TREES
#42 MESH DESCRIP-
TOR Sirolimus EXPLODE All
TREES
#43 MESH DESCRIPTOR
Salicylic Acid EXPLODE All
TREES
#44 MESH DESCRIPTOR
Pentamidine EXPLODE All
TREES
#45 MESH DESCRIP-
TOR Nystatin EXPLODE All
TREES
#46 MESH DESCRIP-
TOR Nifuratel EXPLODE All
TREES
#47 MESH DESCRIP-
TOR Natamycin EXPLODE
All TREES
#48 MESH DESCRIPTOR
Mycobacillin EXPLODE All
TREES
#49 MESH
DESCRIPTORMonensin EX-
PLODE All TREES
#50 MESH DESCRIP-
TOR Miconazole EXPLODE
All TREES
#51 MESH DESCRIPTOR
Mepartricin EXPLODE All
TREES
#52 MESH DESCRIPTOR
ipin or Fluconazole or Flucyto-
sine or glyphosate or Griseoful-
vin or hamycin or Hexetidine
or hydroxyitraconazole or (ICI
adj3 ”195739“) or isocona-
zole or Itraconazole or iturin
or jasplakinolide or Ketocona-
zole or lactoferricin or lapa-
chol or lawsone or leptomycin
or Lucensomycin or Mepar-
tricin or methylamphotericin
or micafungin or Miconazole
or miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Ni-
furatel or nikkomycin or ni-
troxoline or Nystatin or ox-
iconazole or papulacandin or
(pelargonic adj3 acid) or Pen-
tamidine or polygodial or (poly-
oxin adj3 D) or posaconazole
or (potassium adj3 iodate) or
pradimicin or protegrin-1 or
purothionin or pyochelin or
pyrithione or Pyrrolnitrin or
rhizoxin or Rutamycin or (sal-
icylhydroxamic adj3 acid) or
(Salicylic adj3 Acid) or saper-
conazole or (Sch adj3 ”39304“)
or sertaconazole or sinefungin
or Sirolimus or (Sodium adj3
Benzoate) or squalestatin or sul-
conazole or terbinafine or ter-
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (usnic
adj3 acid) or Venturicidins or
vibunazole or voriconazole or
wortmannin).ab,ti,nm
36 (antifung* or ”anti fung*“ or
fungastic or fungicidal or Fun-
gizone or Amphocil or Zonal or
Diflucan or Triflucan or hexal
or Fluco* or Flunazul or Fun-
or Econazole or Ethonium or
fenticonazole or ferroin or Fil-
ipin or Fluconazole or Flucyto-
sine or glyphosate or Griseoful-
vin or hamycin or Hexetidine
or hydroxyitraconazole or (ICI
adj3 ”195739“) or isocona-
zole or Itraconazole or iturin
or jasplakinolide or Ketocona-
zole or lactoferricin or lapa-
chol or lawsone or leptomycin
or Lucensomycin or Mepar-
tricin or methylamphotericin
or micafungin or Miconazole
or miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Ni-
furatel or nikkomycin or ni-
troxoline or Nystatin or ox-
iconazole or papulacandin or
(pelargonic adj3 acid) or Pen-
tamidine or polygodial or (poly-
oxin adj3 D) or posaconazole
or (potassium adj3 iodate) or
pradimicin or protegrin-1 or
purothionin or pyochelin or
pyrithione or Pyrrolnitrin or
rhizoxin or Rutamycin or (sal-
icylhydroxamic adj3 acid) or
(Salicylic adj3 Acid) or saper-
conazole or (Sch adj3 ”39304“)
or sertaconazole or sinefungin
or Sirolimus or (Sodium adj3
Benzoate) or squalestatin or sul-
conazole or terbinafine or ter-
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (usnic
adj3 acid) or Venturicidins or
vibunazole or voriconazole or
wortmannin).tw
71 (antifung* or ”anti fung*“ or
fungastic or fungicidal or Fun-
gizone or Amphocil or Zonal or
acid)
S42 TOPIC: (diallyl near/3
trisulfide)
S43 TOPIC: (Dichlorophen or
diucifon or echinocandin or
Echinocandins or Econazole or
Ethonium or fenticonazole or
ferroin or Filipin or Fluconazole
or Flucytosine or glyphosate
or Griseofulvin or hamycin or
Hexetidine or hydroxyitracona-
zole)
S44 TOPIC: (ICI near/3
”195739“)
S45 TOPIC: (isoconazole or
Itraconazole or iturin or jas-
plakinolide or Ketoconazole
or lactoferricin or lapachol
or lawsone or leptomycin or
Lucensomycin or Mepartricin
or methylamphotericin or mi-
cafungin or Miconazole or
miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Nifu-
ratel or nikkomycin or nitroxo-
line or Nystatin or oxiconazole
or papulacandin)
S46 TOPIC: (pelargonic near/
3 acid)
S47 TOPIC: (Pentamidine or
polygodia)
S48 TOPIC: (polyoxin near/3
”D“)
S49 TOPIC: (potassium near/3
iodate)
S50 TOPIC: (posaconazole or
pradimicin or protegrin-1 or
purothionin or pyochelin or
pyrithione or Pyrrolnitrin or
rhizoxin or Rutamycin)
S51 TOPIC: (salicylhydrox-
amic near/3 acid)
S52 TOPIC: (Salicylic near/3
Acid)
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Lucensomycin EXPLODE All
TREES
#53 MESH DESCRIPTOR
Ketoconazole EXPLODE All
TREES
#54 MESH DESCRIPTOR
Itraconazole EXPLODE All
TREES
#55
MESH DESCRIPTOR Hexe-
tidine EXPLODE All TREES
#56 MESH DESCRIPTOR
Griseofulvin EXPLODE All
TREES
#57
MESH DESCRIPTOR Flucy-
tosine EXPLODE All TREES
#58 MESH DESCRIPTOR
Fluconazole EXPLODE All
TREES
#59 MESH
DESCRIPTOR Econazole EX-
PLODE All TREES
#60 MESH DESCRIPTOR
Echinocandins EXPLODE All
TREES
#61 MESH DESCRIPTOR
Dichlorophen EXPLODE All
TREES
#62 MESH DESCRIPTOR
Cyclosporine EXPLODE All
TREES
#63 MESH DESCRIPTOR
Cycloheximide EXPLODE All
TREES
#64 MESH DESCRIPTOR
Clotrimazole EXPLODE All
TREES
#65 MESH DESCRIPTOR
Filipin EXPLODE All TREES
#66 MESH
DESCRIPTOR Cerulenin EX-
PLODE All TREES
#67
MESHDESCRIPTORCandi-
cidin EXPLODE All TREES
#68 MESH DESCRIPTOR
Brefeldin A EXPLODE All
TREES
gata or Lavisa or Loitin or Ne-
ofomiral or oxifungol or Sola-
cap or 49858 of Beagyne or
”51211“ or Sporanox or Orun-
gal).ab,ti,nm
37 32 or 33 or 34 or 35 or 36
38 31 and 37
Diflucan or Triflucan or hexal
or Fluco* or Flunazul or Fun-
gata or Lavisa or Loitin or Ne-
ofomiral or oxifungol or Sola-
cap or 49858 of Beagyne or
”51211“ or Sporanox or Orun-
gal).tw
72 28 or 29 or 30 or 31 or 32
or 33 or 34 or 35 or 36 or 37 or
38 or 39 or 40 or 41 or 42 or
43 or 44 or 45 or 46 or 47 or
48 or 49 or 50 or 51 or 52 or
53 or 54 or 55 or 56 or 57 or
58 or 59 or 60 or 61 or 62 or
63 or 64 or 65 or 66 or 67 or
68 or 69 or 70 or 71
73 27 and 72
S53 TOPIC: (Sch near/3
”39304“)
S54 TOPIC: (saperconazole or
sertaconazole or sinefungin or
Sirolimus)
S55 TOPIC: (Sodium near/3
Benzoate)
S56 TOPIC: (squalestatin or
sulconazole or terbinafine or
terconazole or thermozymo-
cidin or Thymol or tiocona-
zole or Tolnaftate or Tomatine
or Triacetin or trichostatin or
Trimetrexate or troclosene)
S57 TOPIC: (usnic near/3
acid)
S58 TOPIC: (Venturicidins or
vibunazole or voriconazole or
wortmannin)
S59TOPIC: (antifung* or ”anti
fung*“ or fungastic or fungici-
dal or Fungizone or Amphocil
or Zonal or Diflucan or Triflu-
can or hexal or Fluco* or Flu-
nazul or Fungata or Lavisa or
Loitin or Neofomiral or oxi-
fungol or Solacap or 49858 of
Beagyne or ”51211“ or Spora-
nox or Orungal)
S60 #59 OR #58 OR #57 OR
#56 OR #55 OR #54 OR #53
OR #52 OR #51 OR #50 OR
#49 OR #48 OR #47 OR #46
OR #45 OR #44 OR #43 OR
#42 OR #41 OR #40 OR #39
S61 #60 AND #38
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#69 MESH
DESCRIPTOR Benzoates EX-
PLODE All TREES
#70 MESH DESCRIP-
TOR Azaserine EXPLODE All
TREES
#71 MESH DESCRIPTOR
Antimycin A EXPLODE All
TREES
#72 MESH DESCRIPTOR
Amphotericin B EXPLODE
All TREES
#73 (acivicin or ajoene or
amorolfin or Amphotericin or
anidulafungin or Antimycin or
artemether or aureobasidin or
Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole):TI,AB,
KY
#74 (Candicidin or candidin or
captax or caspofungin or Ceru-
lenin or ciclopirox or cilofun-
gin or Clotrimazole or com-
pactin or cordycepin or cryp-
tophycin or Cycloheximide or
Cyclosporine or (decanoic near
acid) or (diallyl near trisulfide)
or Dichlorophen or diucifon or
echinocandin or Echinocandins
or Econazole or Ethonium):TI,
AB,KY
#75 (fenticonazole or ferroin
or Filipin or Flucytosine or
glyphosate or Griseofulvin or
hamycin or Hexetidine or hy-
droxyitraconazole or (ICI near
”195739“) or isoconazole or
Itraconazole or iturin or jas-
plakinolide or Ketoconazole or
lactoferricin or lapachol or law-
sone or leptomycin or Lucen-
somycin):TI,AB,KY
#76 (Mepartricin or methy-
lamphotericin or micafungin
or Miconazole or miltefosine
or Monensin or monorden
or mucidin or muconaldehyde
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or Mycobacillin or myxothia-
zol or n-hexanal or naftifine
or Natamycin or Nifuratel or
nikkomycin or nitroxoline or
Nystatin or oxiconazole or
papulacandin or (pelargonic
near acid) or Pentamidine or
polygodial or (polyoxin near
D) or posaconazole or (potas-
sium near iodate) or pradimicin
or protegrin-1 or purothionin
or pyochelin or pyrithione or
Pyrrolnitrin):TI,AB,KY
#77 (rhizoxin or Rutamycin or
(salicylhydroxamic near acid) or
(Salicylic near Acid) or saper-
conazole or (Sch near ”39304“)
or sertaconazole or sinefungin
or Sirolimus or (Sodium near
Benzoate) or squalestatin or sul-
conazole or terbinafine or ter-
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (usnic
near acid) or Venturicidins or
vibunazole or voriconazole or
wortmannin):TI,AB,KY
#78 #32 OR #33 OR #34 OR
#35 OR #36 OR #37 OR #38
OR #39 OR #40 OR #41 OR
#42 OR #43 OR #44 OR #45
OR #46 OR #47 OR #48 OR
#49 OR #50 OR #51 OR #52
OR #53 OR #54 OR #55 OR
#56 OR #57 OR #58 OR #59
OR #60 OR #61 OR #62 OR
#63 OR #64 OR #65 OR #66
OR #67 OR #68 OR #69 OR
#70 OR #71 OR #72 OR #73
OR #74 OR #75 OR #76 OR
#77
#79 #31 AND #78
CINAHL (EBSCO) ICTRP ClinicalTrials.gov LILACS
S36 S29 AND S35
S35 S30 OR S31 OR S32 OR
S33 OR S34
rhinitis AND fungal OR rhini-
tis AND antifungal OR sinusi-
via Cochrane Register of
Studies
TW:rhinit* OR TW:
sinusit* OR TW:rhinosinusitis
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S34 TX (antifung* or ”anti
fung*“ or fungastic or fungici-
dal or Fungizone or Amphocil
or Zonal or Diflucan or Triflu-
can or hexal or Fluco* or Flu-
nazul or Fungata or Lavisa or
Loitin or Neofomiral or oxi-
fungol or Solacap or 49858 of
Beagyne or ”51211“ or Spora-
nox or Orungal)
S33 TX (Candicidin or can-
didin or captax or caspofun-
gin or Cerulenin or ciclopirox
or cilofungin or Clotrimazole
or compactin or cordycepin
or cryptophycin or Cyclohex-
imide or Cyclosporine or (de-
canoic N3 acid) or (diallyl
N3 trisulfide) or Dichlorophen
or diucifon or echinocandin
or Echinocandins or Econa-
zole or Ethonium or fenti-
conazole or ferroin or Fil-
ipin or Fluconazole or Flucy-
tosine or glyphosate or Grise-
ofulvin or hamycin or Hexeti-
dine or hydroxyitraconazole or
(ICI N3 ”195739“) or isocona-
zole or Itraconazole or iturin
or jasplakinolide or Ketocona-
zole or lactoferricin or lapa-
chol or lawsone or leptomycin
or Lucensomycin or Mepar-
tricin or methylamphotericin
or micafungin or Miconazole
or miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Ni-
furatel or nikkomycin or ni-
troxoline or Nystatin or ox-
iconazole or papulacandin or
(pelargonic N3 acid) or Pen-
tamidine or polygodial or (poly-
oxin N3 D) or posaconazole
or (potassium N3 iodate) or
pradimicin or protegrin-1 or
purothionin or pyochelin or
tis AND fungal OR sinusitis
AND antifungal or CRS AND
fungal OR CRS AND antifun-
gal OR AFRS AND antifun-
gal OR AFRS AND fungal OR
rhinosinusitis AND fungal OR
rhinosinusitis AND antifungal
1 rhinosinusitis or nasosinusitis
or pansinusitis or ethmoiditis
or sphenoiditis AND INSEG-
MENT
2 kartagener* near syndrome*
AND INSEGMENT
3 sinus* or rhinitis* or sinonasal
AND INSEGMENT
4 (nose or nasal or rhino*)AND
(papilloma* or polyp* or fung*)
AND INSEGMENT
5 rhinopolyp* or CRSwNP
AND INSEGMENT
6 CRSsNP or AFS or AFRS
AND INSEGMENT
7 #1 OR #2 OR #3 OR #4 OR
#5 AND INSEGMENT
8 antifung* or ”anti fung*“ or
fungastic or fungicidal or Fun-
gizone or Amphocil or Zonal or
Diflucan or Triflucan or hexal
or Fluco* or Flunazul or Fun-
gata or Lavisa or Loitin or Neo-
fomiral or oxifungol or Solacap
or 49858 of Béagyne or 51211
or Sporanox or Orungal AND
INSEGMENT
9 acivicin or ajoene
or amorolfin or Amphotericin
or anidulafungin or Antimycin
or artemether or aureobasidin
or Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole AND
INSEGMENT
10 Candicidin or candidin or
captax or caspofungin or Ceru-
lenin or ciclopirox or cilofun-
gin or Clotrimazole or com-
pactin or cordycepin or cryp-
tophycin or Cycloheximide or
Cyclosporine or (decanoic near
acid) or (diallyl near trisulfide)
or Dichlorophen or diucifon
or echinocandin or Echinocan-
dins or Econazole or Ethonium
AND INSEGMENT
OR TW:rinit* OR (TW:nose
AND TW:polyp*) OR (TW:
nasal AND TW:polyp*) OR
(TW: polipos AND TW:nasa*)
OR TW:CRSsNP OR TW:
CRSwNP OR TW:CRS OR
TW:AFRS
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pyrithione or Pyrrolnitrin or
rhizoxin or Rutamycin or (sali-
cylhydroxamicN3 acid) or (Sal-
icylic N3 Acid) or sapercona-
zole or (Sch N3 ”39304“) or
sertaconazole or sinefungin or
Sirolimus or (Sodium N3 Ben-
zoate) or squalestatin or sul-
conazole or terbinafine or ter-
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (usnic
N3 acid) or Venturicidins or
vibunazole or voriconazole or
wortmannin)
S32 TX (acivicin or ajoene
or amorolfin or Amphotericin
or anidulafungin or Antimycin
or artemether or aureobasidin
or Azaserine or bafilomycin or
Benzoates or bifonazole or blas-
ticidin or Brefeldin or bute-
nafine or butoconazole)
S31 (MH ”Mycoses/DT/TH“)
S30
(MH “Antifungal Agents+”) or
(MH “Amphotericin B+”) or
(MH “Antimycin A+”) or (MH
“Azaserine+”) or (MH “Ben-
zoates+”) or (MH “Brefeldin
A+”) or (MH “Candicidin+”)
or (MH “Cerulenin+”) or (MH
“Clotrimazole+”) or (MH “Cy-
cloheximide+”) or (MH “Cy-
closporine+”)
or (MH “Dichlorophen+”) or
(MH “Echinocandins+”) or
(MH “Econazole+”) or (MH
“Filipin+”) or (MH “Flucona-
zole+”)
or (MH “Flucytosine+”) or
(MH “Griseofulvin+”) or (MH
“Hexetidine+”) or (MH “Itra-
conazole+”) or (MH “Keto-
conazole+”) or (MH “Lucen-
somycin+”) or (MH “Mepar-
tricin+”) or (MH “Micona-
11 fenticonazole or ferroin
or Filipin or Flucytosine or
glyphosate or Griseofulvin or
hamycin or Hexetidine or hy-
droxyitraconazole or (ICI near
”195739“) or isoconazole or
Itraconazole or iturin or jas-
plakinolide or Ketoconazole or
lactoferricin or lapachol or law-
sone or leptomycin or Lucen-
somycin AND INSEGMENT
12 Mepartricin or methylam-
photericin
or micafungin or Miconazole
or miltefosine or Monensin or
monorden or mucidin or mu-
conaldehyde orMycobacillin or
myxothiazol or n-hexanal or
naftifine or Natamycin or Ni-
furatel or nikkomycin or ni-
troxoline or Nystatin or ox-
iconazole or papulacandin or
(pelargonic near acid) or Pen-
tamidine or polygodial or (poly-
oxin near D) or posacona-
zole or (potassium near iodate)
or pradimicin or protegrin-1
or purothionin or pyochelin
or pyrithione or Pyrrolnitrin
AND INSEGMENT
13 rhizoxin or Rutamycin or
(salicylhydroxamic near acid) or
(Salicylic near Acid) or saper-
conazole or (Sch near ”39304“)
or sertaconazole or sinefungin
or Sirolimus or (Sodium near
Benzoate) or squalestatin or sul-
conazole or terbinafine or ter-
conazole or thermozymocidin
or Thymol or tioconazole or
Tolnaftate or Tomatine or Tri-
acetin or trichostatin or Trime-
trexate or troclosene or (us-
nic near acid) or Venturicidins
or vibunazole or voriconazole
or wortmannin AND INSEG-
MENT
14 #8 OR #9 OR #11 OR #
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zole+”) or (MH “Monensin+”)
or (MH “Mycobacillin+”) or
(MH “Natamycin+”) or (MH
“Nifuratel+”)
or (MH “Nystatin+”) or (MH
“Pentamidine+”) or (MH “Ru-
tamycin+”) or (MH “Salicylic
Acid+”) or (MH “Sirolimus+”)
or (MH “Sodium Benzoate+”)
or (MH “Thymol+”) or (MH
“Tomatine+”) or (MH “Tolnaf-
tate+”) or (MH“Triacetin+”) or
(MH “Trimetrexate+”) or (MH
“Venturicidins+”)
S29 S18 OR S19 OR S20 OR
S21 OR S26 OR S27 OR S28
S28 TX (rhinopolyp* or CR-
SwNP)
S27 TX ((nose or nasal or
rhino* or rhinitis or sinus* or
sinonasal) N3 (papilloma* or
polyp* or fung*))
S26 S24 AND S25
S25 (MH ”Polyps+“)
S24 S22 OR S23
S23 (MH ”Nose Diseases+“)
S22 (MH ”Nose+“)
S21 (MH ”Rhinitis+/MI“) OR
(MH ”Nasal Mucosa+/MI“)
S20 (MH ”Paranasal Sinus Dis-
eases+/MI“) OR (MH
”Paranasal Sinuses+/MI“)
S19 (MH ”Nasal Polyps+“)
S18 S15 OR S16 OR S17
S17 TX ((sinusitis or rhinitis)
n3 (chronic or persis* or recur-
rent* or fung*))
S16 TX (CRSsNP or AFS or
AFRS)
S15 S8 AND S14
S14 S9 OR S10 OR S11 OR
S12 OR S13
S13 TX (chronic or persis*
or recurrent* or fung* or
eosinophil* or mycetoma* or
Maduromycos* or Actinomyce-
toma* or Eumycetoma*)
S12 (MH ”Mycetoma+“)
S11 (MH ”Fungi+“)
10 OR #12 OR #13 AND IN-
SEGMENT
15 #7 AND#14 AND INSEG-
MENT
16 (NCT*):AU AND INSEG-
MENT
17 #15 AND #16 AND IN-
SEGMENT
via ClinicalTrials.gov
( rhinitis OR sinusitis OR
rhinosinusitis OR nasosinusi-
tis OR pansinusitis OR eth-
moiditis OR sphenoiditis OR
CRSsNP OR AFS OR AFRS
OR rhinopolyps OR CRSwNP
OR nasal AND polyp OR
nose AND polyp OR fun-
gal AND sinus OR fungus
AND sinus OR rhino AND
polyp ) AND ( Antifungal OR
antifungus OR “anti fungal”
OR “anti fungus” OR fungas-
tic OR fungicidal OR Fungi-
zone OR Amphocil OR Zonal
OR Diflucan OR Triflucan
OR hexal OR Fluco OR Flu-
nazul OR Fungata OR Lav-
isa OR Loitin OR Neofomiral
OR oxifungol OR Solacap OR
49858 of Béagyne OR 51211
OR Sporanox OR Orungal
OR acivicin OR ajoene OR
amorolfin OR Amphotericin
OR anidulafungin OR An-
timycin OR artemetherOR au-
reobasidin OR Azaserine OR
bafilomycin OR Benzoates OR
bifonazole OR blasticidin OR
Brefeldin OR butenafine OR
butoconazole OR Candicidin
OR candidin OR captax OR
caspofungin ORCeruleninOR
ciclopirox OR cilofungin OR
Clotrimazole OR compactin
OR cORdycepin OR crypto-
phycin OR Cycloheximide OR
CyclospORine OR decanoic
AND acid OR diallyl AND
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S10 (MH ”Chronic Disease+“)
S9 (MH ”Recurrence+“)
S8 S1ORS2ORS3ORS4OR
S5 OR S6 OR S7
S7TX ((maxilla* or frontal*) n3
sinus*)
S6 TX (inflamm* n3 sinus*)
S5 TX kartagener* n3 syn-
drome*
S4 TX rhinosinusitis or nasos-
inusitis or pansinusitis or eth-
moiditis or sphenoiditis
S3 (MH ”Paranasal Sinus Dis-
eases+“)
S2 (MH ”Paranasal Sinuses+“)
S1 (MH ”Rhinitis+“)
trisulfide OR DichlORophen
OR diucifon OR echinocandin
OR Echinocandins OR Econa-
zole OR Ethonium OR fenti-
conazoleOR ferroinORFilipin
OR Flucytosine OR glyphosate
OR Griseofulvin OR hamycin
OR Hexetidine OR hydrox-
yitraconazole OR ICI AND
”195739“ OR isoconazole OR
Itraconazole OR iturin OR jas-
plakinolide OR Ketoconazole
OR lactoferricin OR lapachol
OR lawsone OR leptomycin
OR Lucensomycin ORMepar-
tricin OR methylamphotericin
OR micafungin OR Micona-
zole OR miltefosine OR Mon-
ensin ORmonORden ORmu-
cidin OR muconaldehyde OR
Mycobacillin OR myxothiazol
OR n-hexanal OR naftifine
OR Natamycin OR Nifuratel
OR nikkomycin OR nitrox-
oline OR Nystatin OR oxi-
conazole OR papulacandin OR
pelargonic AND acid OR Pen-
tami-
dine OR polygodial OR poly-
oxin AND D OR posacona-
zole OR potassium AND io-
date OR pradimicin OR pro-
tegrin-1 OR purothionin OR
pyochelin OR pyrithione OR
Pyrrolnitri OR rhizoxin OR
Rutamycin OR salicylhydrox-
amic AND acid OR Salicylic
AND Acid OR saperconazole
OR SchAND”39304“ OR ser-
taconazole OR sinefungin OR
Sirolimus OR Sodium AND
Benzoate OR squalestatin OR
sulconazole OR terbinafine OR
terconazole OR thermozymo-
cidin OR Thymol OR tiocona-
zole OR Tolnaftate OR Toma-
tine OR Triacetin OR tricho-
statin ORTrimetrexate OR tro-
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closene OR usnic AND acid
OR Venturicidins OR vibuna-
zole OR voriconazole ORwort-
mannin ) ANDEXACT ”Inter-
ventional“ [STUDY-TYPES]
Appendix 2. Data extraction form
REF ID: Study title:
Date of extraction: Extracted by:
General comments/notes (internal for discussion):
Flow chart of trial
Group A (Intervention) Group B (Comparison)
No. of people screened
No. of participants randomised - all
No. randomised to each group
No. receiving treatment as allocated
No. not receiving treatment as allocated
- Reason 1
- Reason 2
No. dropped out
(no follow-up data for any outcome avail-
able)
No. excluded from analysis1 (for all out-
comes)
- Reason 1
- Reason 2
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1This should be the people who received the treatment and were therefore not considered ’dropouts’ but were excluded from all
analyses (e.g. because the data could not be interpreted or the outcome was not recorded for some reason)
Information to go into ’Characteristics of included studies’ table
Methods X arm, double/single/non-blinded, [multicentre] parallel-group/
cross-over/cluster-RCT, with x duration of treatment and x dura-
tion of follow-up
Participants Location: country, no of sites etc.
Setting of recruitment and treatment:
Sample size:
• Number randomised: x in intervention, y in comparison
• Number completed: x in intervention, y in comparison
Participant (baseline) characteristics:
• Age:
• Gender:
• Main diagnosis: [as stated in paper]
• Polyps status: x% with polyps/no information [add info on
mean polyps score if available]
• Presence of allergic fungal rhinosinusitis: x% with AFRS
[add info if available]
• Presence of eosinophilic CRS: x% with eosinophilic CRS
[add info if available]
• Previous sinus surgery status: [x% with previous surgery]
• Other important effect modifiers, if applicable (e.g. aspirin
sensitivity, comorbidities of asthma):
Inclusion criteria: [state diagnostic criteria used for CRS, polyps
score if available]
Exclusion criteria:
Interventions Intervention (n = x): drug name, method of administration, dose
per day/frequency of administration, duration of treatment
Comparator group (n = y):
Use of additional interventions (common to both treatment arms)
:
Outcomes Outcomes of interest in the review:
Primary outcomes:
• Health-related quality of life, disease-specific
• Disease severity symptom score
• Significant adverse effects (systemic antifungals): hepatic
toxicity
Secondary outcomes:
• Health-related quality of life, generic
• Adverse effects (topical antifungals): epistaxis, headache,
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local discomfort (mild burning, itching)
• Adverse effects (systemic antifungals): gastrointestinal
disturbances, allergic reactions.
• Endoscopy (polyps size or overall score)
• CT scan
Other outcomes reported by the study:
• [List outcomes reported but not of interest to the review]
Funding sources ’No information provided’/’None declared’/State source of fund-
ing
Declarations of interest ’No information provided’/’None declared’/State conflict
Notes
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Quote: ”…“
Comment:
Allocation concealment (selection bias) Quote: ”…“
Comment:
Blinding of participants and personnel
(performance bias)
Quote: ”…“
Comment:
Blinding of outcome assessment (detection
bias)
Quote: ”…“
Comment:
Incomplete outcome data (attrition bias) Quote: ”…“
Comment:
Selective reporting (reporting bias) Quote: ”…“
Comment:
Other bias (see section 8.15)
Insensitive/non-validated instrument?
Quote: ”…“
Comment:
Other bias (see section 8.15) Quote: ”…“
Comment:
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Findings of study: continuous outcomes
Results (continuous data table)
Outcome Group A Group B Other summary stats/Notes
Mean SD N Mean SD N Mean difference (95% CI), P values etc.
Disease-spe-
cific HRQL
(instrument
name/range)
Time point:
Generic
HRQL
(instrument
name/range)
Time point:
Symptom
score (overall)
(instrument
name/range)
Time point:
Added total -
if scores re-
ported
separately for
each symptom
(range)
Time point:
Nasal
blockage/
obstruction/
congestion
(instrument
name/range)
Nasal
discharge
(instrument
name/range)
Facial pain/
pressure
(instrument
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name/range)
Smell (reduc-
tion)
(instrument
name/range)
Headache
(instrument
name/range)
Cough (in
children)
(instrument
name/range)
Polyp size
(instrument
name/range)
CT score
(instrument
name/range)
Comments:
Results (dichotomous data table)
Outcome Ap-
plicable review/
intervention
Group A Group B Other summary
stats/notes
No. of people
with events
No. of people
analysed
No. of people
with events
No. of people
analysed
P values, RR
(95% CI), OR
(95% CI)
Renal/hepatic
toxicity
Systemic
antifungals
Headache Topical antifun-
gals
Gastrointestinal
disturbances
(diarrhoea, nau-
sea, vom-
Topical antifun-
gals
Systemic
antifungals
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iting, stomach ir-
ritation)
Epistaxis Topical antifun-
gals
Local discomfort Topical antifun-
gals
Anaphy-
laxis or other se-
rious allergic re-
actions
Systemic
antifungals
Comments:
C O N T R I B U T I O N S O F A U T H O R S
Karen Head wrote the review text with the help of the other authors.
Lee Yee Chong, Claire Hopkins and Carl Philpott reviewed and edited the review text.
Lee Yee Chong and Karen Head completed initial screening of abstracts, Lee Yee Chong, Karen Head and Steve Sharp completed
screening of the updated search.
Karen Head, Lee Yee Chong, Claire Hopkins and Carl Philpott reviewed the full-text papers for inclusion.
Karen Head and Steve Sharp completed the data extraction.
D E C L A R A T I O N S O F I N T E R E S T
Karen Head: none known.
Steve Sharp: none known.
Lee Yee Chong: none known.
Claire Hopkins: I have received financial support from several companies involved in producing instruments for sinus surgery: Acclarent,
Sinusys, Cryolife and Medtronic.
Carl Philpott: I have previously received consultancy fees from the companies Acclarent, Navigant, Aerin Medical and Entellus, and
am a trustee of the patient charity Fifth Sense.
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
Infrastructure funding for Cochrane ENT
N O T E S
This review will update and replace the previously published review ’Topical and systemic antifungal therapy for the symptomatic
treatment of chronic rhinosinusitis’ (Sacks 2011).
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